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ABSTRACT 
Irritable bowel syndrome (IBS) is a multifactorial and complex disease categorized in the 
functional gastrointestinal disorders (FGIDs) with an intricate pathogenesis yet far from 
understood. The prevalence and burden of the FGIDs has urged the need to improve our 
understanding of them and recent findings have led us to realize that there are biochemical 
and structural alterations playing roles in their etiology. This thesis has concentrated on a 
number of factors including altered intestinal motility, pain perception, genetic 
predisposition, and gut microbiota in order to obtain a better understanding of the interplay 
between these factors in the generation of gastrointestinal (GI) symptoms. To achieve this, 
we have carried out five studies exploiting data from a Swedish data-rich general 
population-based cohort, namely PopCol, and some other cohorts. 
In the first study, to investigate the link between gut microbiota and gut transit time (as an 
objective means to quantify GI functional abnormalities) we studied the association 
between different indices of fecal microbiota composition with stool consistency and stool 
frequency (as surrogates for gut transit time) in the PopCol cohort. The obtained results 
provide more support for the already reported association between gut microbiota and stool 
consistency and also revealed an even stronger association between the composition of 
fecal microbiota and stool frequency. 
To study the association between one of the most common symptoms of FGIDs, i.e. 
abdominal pain, and gut microbiota in the second study, data of 159 individuals from 
PopCol cohort (including 52 individuals who reported pain) was inspected. Results 
indicated an association between fecal microbiota composition and abdominal pain 
occurrence as well as its frequency, duration, and severity. Also, we could provide more 
evidence for the negative association of Prevotella with pain in the general population. 
In the third study, to investigate the genetic biology of stool frequency, we exploited data 
from two general population-based cohorts, PopCol and LifeLines-Deep, and carried out a 
genome-wide association study (GWAS) followed by a meta-analysis. Gene set enrichment 
analysis was performed on the resulting gene list. Although, possibly due to limited sample 
size, none of the association tests revealed genome-wide significant results, we could 
identify excellent functional candidate genes and more interestingly, the results from the 
post-GWAS analysis suggested xenobiotic metabolism and ion channel activity as two 
plausible underlying mechanisms for regulation of the stool frequency. This result pointing 
at the link between ion channel activity and bowel function in addition to the results of 
another study which revealed that 2.2% of IBS patients carry a mutation in a voltage-gated 
channel gene (SCN5A), led us to the fourth study. In this study, 14 single nucleotide 
polymorphisms (SNPs) spread over TRPM8 (a gene involved in GI-related ion channel 
activity) were investigated in association to IBS and its subtypes in a cohort of IBS cases 
and controls followed by a meta-analysis of the results of this study and the GWAS of IBS 
(already published by our lab). Subsequently, PopCol data was used to study the 
association between TRPM8 genotype variants and stool consistency. Logistic regression 
analysis revealed significant associations between different variants of TRPM8 gene and 
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predisposition to IBS, which was restricted to the constipation-related subtypes of IBS 
(IBS-C and IBS-M). This result was confirmed by the meta-analysis. Moreover, a negative 
correlation between all IBS-C/M predisposing risk alleles and stool consistency was 
obtained from investigating the PopCol cohort. Finally, considering the importance of 
genes and diet in the susceptibility to IBS, in a nutrigenetic approach, we studied the 
sucrase-isomaltase (SI) gene variants (congenital defective form of this gene results from 
rare mutations and is characterized by abdominal pain, diarrhea, and bloating) for their 
potential relevance to IBS in the fifth study. To do this, the four most known congenital 
sucrase-isomaltase deficiency (CSID) mutations in addition to a SI coding SNP 
(p.Val15Phe) were screened in a multicenter cohort of IBS cases and controls. The effect of 
this SNP on the function of SI was also inspected in vitro. Finally, we analyzed p.Val15Phe 
genotype in association to fecal microbiota and stool frequency in PopCol cohort. Our 
results indicated that the four CSID mutations and the common variant were more common 
in patients than asymptomatic controls. The in vitro study indicated 35% reduced enzymatic 
activity for the SI protein with 15Phe compared to 15Val. Investigating PopCol samples, 
15Phe copies correlated with stool frequency and the abundance of fecal Parabacteroides.  
In summary, in this thesis we succeeded in providing additional strong evidence for the 
importance of human genes (TRPM8 and SI) in the development of IBS and its symptoms. 
Moreover, we demonstrated a link between some of the important IBS symptoms, i.e. 
abdominal pain and altered stool frequency with gut microbiota composition in the general 
population. Taken together, this thesis contributes to a better understanding of the interplay 
between several factors in the generation of GI symptoms. The information we report here 
may contribute to translational opportunities for the stratification and eventual management 
of individuals with IBS and other FGIDs.  
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1  FUNCTIONAL GASTROINTESTINAL DISORDERS 
Functional gastrointestinal disorders (FGIDs), conceptualized as disorders of the gut-brain 
interaction, are the most common gastrointestinal-related disorders worldwide (1, 2). FGIDs 
are defined as illness experiences by sufferers, which are mainly diagnosed by symptoms and 
can affect all people regardless of gender, age, race, etc. although their prevalence could be 
influenced by these factors (3). The etiology of FGIDs is not well-characterized yet but 
impairment in the physiological factors such as gut motility, immune system, microbiota 
composition and diet in a complex interaction with psycho-social factors as well as the 
genetic background has been implicated in the development of the vast spectrum of these 
diseases (1). The classification of FGIDs in adults based on ROME IV (2016) has been 
illustrated in figure 1A (1, 2). Among these six categories, functional bowel disorders (FBDs) 
are one of the most prevalent ones. 
FBDs encompass a wide range of chronic gastrointestinal (GI) disorders defined by common 
symptoms of abdominal pain, distention, bloating and alterations in bowel movements and in 
adults are categorized into six different classes (figure 1A). Except for the last class, namely 
Opioid-induced constipation which can create the symptoms similar to the functional 
constipation but has a specific etiology and is distinct from the other FBDs, there is big 
overlap between the other classes (figure 1B). In the definition of all these classes of FBDs, 
four different criteria of chronicity, frequency, current activity and lack of physiologic 
abnormality have been highlighted. In other words, a disorder could be labeled as an FBD if 
it has been presented for at least 1 day per week (on average) within the last three months, 
continued for at least 6 months at the time of presentation and no pathologic origin could be 
identified for it through diagnostic examinations (3).  
1.1 Irritable bowel syndrome 
Irritable bowel syndrome (IBS) is the most common FGID (4) with different clinical 
appearances. Based on ROME IV, this disorder is characterized by ‘recurrent abdominal 
pain’ accompanied by at least two of the following three criteria: 
1. In relation to defecation 
2. In association to an alteration in stool frequency 
3. In association to an alteration in stool consistency (appearance of the stool) 
Also, to be diagnosed as an IBS sufferer, the patient should not have any alarming signs 
including more than 10% unintended weight loss in 3 months, lower GI bleeding (in the 
absence of hemorrhoids or anal fissures), and a positive family history of colon cancer (3). 
However, it should be noted that ROME IV is the most updated version of the ROME criteria 
and although it will be a valuable tool for upcoming research, all of the so-far published 
investigations, including the papers in this thesis, have exploited the older versions of II and 
III. Noteworthy, the present definition has been stated based on a few amendments to ROME 
III criteria such as omission of ‘discomfort’ from the definition, modification of the phrase 
‘improvement with defecation’ to ‘relation to defecation’ and elimination of the word ‘onset’ 
from the second and third IBS criteria.  
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Figure 1.A. Classification of functional gastrointestinal disorders in adults (1). 
B. FBDs’ conceptual framework. This figure displays the existing overlap between five categories of FBDs. 
Reprinted from Gastroenterology, 150/6, Lacy BE et al., Bowel Disorders, 1393–1407, Copyright (2016), 
with permission from Elsevier. 
A. Esophageal Disorders 
A1. Functional chest pain  
A2. Functional heartburn  
A3. Reflux hypersensitivity 
A4. Globus 
A5. Functional dysphagia 
B. Gastroduodenal Disorders 
B1. Functional dyspepsia  
 B1a. Postprandial distress syndrome 
 B1b. Epigastric pain syndrome  
B2. Belching disorders  
 B2a. Excessive supragastric belching  
 B2b. Excessive gastric belching 
B3. Nausea and vomiting disorders 
 B3a. Chronic nausea vomiting syndrome  
 B3b. Cyclic vomiting syndrome  
 B3c. Cannabinoid hyperemesis 
syndrome  
B4. Rumination syndrome 
 C. Bowel Disorders 
 C1. Irritable bowel syndrome  
     IBS with predominant constipation  
     IBS with predominant diarrhea  
     IBS with mixed bowel habits  
     IBS unclassified  
 C2. Functional constipation 
 C3. Functional diarrhea 
 C4. Functional abdominal   
bloating/distension 
 C5. Unspecified functional bowel disorder 
 C6. Opioid-induced constipation 
E. Gallbladder and Sphincter of Oddi 
(SO) Disorders 
E1. Biliary pain 
 E1a. Functional gallbladder disorder 
 E1b. Functional biliary SO disorder 
E2. Functional pancreatic SO disorder 
D. Centrally Mediated Disorders of 
Gastrointestinal Pain 
D1. Centrally mediated abdominal pain 
syndrome  
D2. Narcotic bowel syndrome/ 
Opioid-induced GI hyperalgesia 
F. Anorectal Disorders 
F1. Fecal incontinence  
F2. Functional anorectal pain  
 F2a. Levator ani syndrome  
 F2b. Unspecified functional anorectal pain 
 F2c. Proctalgia fugax  
F3. Functional defecation disorders 
 F3a. Inadequate defecatory propulsion 
 F3b. Dyssynergic defecation 
A 
B 
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Furthermore, the frequency of the appearance of the symptoms has been changed from ‘at 
least 3 days per month’ to ‘at least 1 day per week during the past 3 months’ (5, 6). 
Moreover, it should be acknowledged that the consensus-based ROME criteria have been 
developed to compensate for the lack of any reliable diagnostic biomarker or test and have 
considerable limitations to be used by clinicians in their daily practice. In other words, 
meeting the criteria is especially useful/valuable for selecting the study samples for the 
clinical research and the symptom-based criteria do not provide a high positive predictive 
value (ROME III: 45.2%, 95%CI 41.1-49.4) to aid physicians in making a positive diagnosis 
of IBS (7). On the other hand, the unclear pathophysiological nature of this disorder, directs 
physicians towards symptom suppressive treatments which are mainly based on a trial and 
error approach and do not result in a persistent cure (8). To overcome these limitations and 
given the considerable burden of IBS on the different levels of patient, society and the health 
system (described later), movement toward an individualized diagnosis and treatment for this 
disorder looks inevitable.  
1.1.1 IBS classification 
Trying to expand the knowledge of the potential underlying mechanisms of the disease as 
well as providing clinicians and researchers with a better tool for a more effective 
diagnosis/treatment and a more reliable case recruitment, IBS has been categorized into four 
different classes (figure 2). This classification is according to the stool consistency of the 
patients defined based on the Bristol stool form scale (BSFS) for the days with alteration in 
the stool form. Indeed, this classification is more reliable if patients suffer from the symptom 
(abnormal bowel habits) on at least four days a month (3, 6).  
 IBS with predominant constipation (IBS-C): a patient is categorized in IBS-C class if his 
stool is hard (1 or 2 on BSFS) in more than 25% of the defecations. Moreover, less than 
25% of his bowel movements should be loose (6 or 7 on BSFS).  
 
 IBS with predominant diarrhea 
(IBS-D): a patient is classified 
as suffering from IBS-D if 
more than 25% of his 
defecations are loose (6 or 7 
on BSFS) and less than 25% of 
them are hard (1 or 2 on 
BSFS). 
 
 IBS with mixed bowel habits 
(IBS-M): IBS patients with > 
25% of loose bowel movement 
(6 or 7 on BSFS) and > 25% 
of hard (1 or 2 on BSFS) are 
considered suffering from 
mixed IBS. 
 
 IBS unclassified (IBS-U): If 
Figure 2. Subtypes of IBS. 
Reprinted from Gastroenterology, 150/6, Lacy BE et al., 
Bowel Disorders, 1393–1407, Copyright (2016), with 
permission from Elsevier. 
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the bowel habits cannot be classified into any of the above-mentioned 3 categories while 
the patient has diagnostic criteria for IBS, IBS-U term is applied. 
1.1.2 IBS epidemiology and burden 
A meta-analysis published in 2012 on roughly 261,000 individuals from 80 studies reported a 
world-wide prevalence of 11.2% (95%CI: 9.8%-12.8%) for IBS (figure 3) (9). However, 
another review article published in 2017 with a bigger sample size (> 288,000) could not 
provide a single world-wide prevalence rate due to the vast variation in the methodological 
approaches. In this study, the mean prevalence of IBS among different countries was reported 
between 35.5% (in Mexico) to 1.1% (in France and Iran) (10). Also, the incidence of IBS has 
been reported to be 1.35% in the United States (11) and 1.5% in the United Kingdom (12) 
(both over 12 years follow-up). In general, the prevalence of IBS is considered higher in 
women and in younger adults (less than 50 years) (9). However, classifying IBS into three 
categories of mild (40% of cases), moderate (35% of cases) and severe (25% of cases), 
changes these estimations to some extent. For example, in the mild version of the disease, the 
prevalence of IBS is equal between men and women while it is much more common in 
women when it comes to the severe type of the disease. Also, the mild version of IBS is more 
prevalent among older people while younger individuals suffer more from the severe form, 
and the moderate version of the disease is equally common in both age categories (1).  
On the other hand, IBS has a considerable impact on the work productivity as well as the 
quality of life (QOL) of the sufferers, accompanied by a substantial economic burden on the 
health system resources (13, 14). Intriguingly, a review article in 2014 has demonstrated that 
Figure 3. IBS prevalence in population studies around the world. Reprinted by permission from 
Macmillan Publishers Ltd: [Nature Reviews Disease Primers] (Enck P et al. Irritable bowel 
syndrome. Nat Rev Dis Primers 2016;2:16014), copyright (2016). 
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IBS patients are ready to give up between 10 to 15 years of their residual life expectancy (on 
average) in order to get rid of IBS immediately (15).  
1.1.3 IBS pathophysiology 
IBS is a multifactorial and complex disorder with convoluted underlying pathogenesis yet far 
from understood. The current knowledge implies a lack of any overt structural or organic 
abnormalities in this disorder and IBS, as well as the other FGIDs, is traditionally called 
‘functional’. However, the importance of these diseases with regards to their prevalence and 
burden has urged the need to improve our understanding of them and recent findings have led 
us to admit that there are biochemical and structural alterations which are playing a role in the 
development of at least a subset of these disorders, particularly in IBS (6, 16, 17) (figure 4).  
 
Impaired intestinal permeability is one of the potential underlying pathophysiologies with 
support from several bodies of evidence. Although this abnormal situation is implicated 
mainly in the commencement of IBS-D and specifically post-infectious IBS, it could be 
considered as a possible mechanism in other classes of IBS too. Based on the present 
evidence, food and food allergy, bile acids, microbiota, genetic and epigenetic predisposition 
Bile acid malabsorption 
Neuropeptides Altered CNS structure 
Pain perception 
Diet / Digestive 
enzyme insufficiency 
Altered intestinal transit 
Disturbed gut 
microbiota 
Genetic predisposition  
Mucosal immune dysregulation  
Impaired intestinal permeability 
G
u
t 
B
ra
in
 a
xi
s 
B
rain
 -G
u
t axis 
Figure 4. Pathophysiological factors proposed to be implicated in the development of IBS. Factors in 
the bold font have been studied in this thesis project. 
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probably through different mechanisms such as alteration of gene expression and protein 
translation of tight junctions can increase the intestinal permeability. It has been demonstrated 
that impaired intestinal permeability is linked to immune system activation, pain, and 
diarrhea which are common symptoms of IBS (18, 19).  
Mucosal immune dysregulation is another mechanism postulated to play a role in the 
development of FGIDs (17). The main cells involved in the mucosal immune system are T 
cells, mononuclear phagocytes (including monocytes, macrophages, and dendritic cells), 
innate lymphoid cells, and other innate immune cells. Dysregulation of the mucosal immune 
system has been implicated in many of the GI disorders but could be specifically important in 
FGIDs. Among them, the pathway related to activation of mast cells by IL-4, secreted locally 
by T cells (T-helper 2), is of particular interest (17). Activation of the mast cells, through 
different mechanisms, could eventually result in the impaired intestinal permeability and 
visceral hypersensitivity (20, 21). The activity and number of mast cells have been shown to 
be increased in IBS patients (22).  
Bile acid malabsorption has been recorded in more than 25% of IBS-D patients. Bile acids 
are produced by the liver and excreted into the small intestine to help absorption of dietary 
fats. As part of the enterohepatic circulation, they should be reabsorbed in the last section of 
the small intestine and if this step is defective (for any reason), the bile acids reach the colon 
and through various mechanisms such as acceleration of colonic transit could result in 
different IBS symptoms including abdominal pain, diarrhea, and bloating (19, 23).  
Altered CNS structure could be another key player in the development of IBS which has been 
investigated in different studies (24-27). However, the results are not so conclusive yet which 
could be related to the heterogeneity and inadequacy of the samples. Probably the most 
prevalent finding in the brain of the IBS patient so far is cortical thinning which has 
constantly been reported in different segments of the brain of the patients in comparison to 
the controls (24-27). Also, interestingly, a recent study has found association between CNS 
structure and specific microbiota in a subset of IBS patients (28) 
Neuropeptides are other potential players in the generation of IBS. Different neuropeptides 
have been demonstrated to be associated with FGIDs and IBS, among them one can mention 
gastrin, motilin, pancreatic polypeptide (29), ghrelin(30), leptin(31), substance P (32), 
neuropeptide Y(33) and so forth, which have different mechanisms to induce IBS, of which 
activation of mast cells could be a prominent candidate. 
Brain-Gut axis or Gut-Brain axis Although IBS has been conventionally considered as a 
brain-gut axis disorder, in up to 50% of the patients it has emerged as a gut to brain pathway 
illness. It means that it could start with a psychological distress accompanied by an abnormal 
stress response in a genetically vulnerable individual and result in alteration of intestinal 
permeability and consequently and through a chain of events end in IBS or the trigger could 
be from the gut such as an alteration in the gut microbiota composition (like in post-infectious 
IBS). This could then initiate a cascade of events such as releasing of the inflammatory 
mediators which in the end could engage the central nervous system and complete the puzzle 
of IBS symptoms (6, 19). Nevertheless, due to the importance of gut microbiota in the 
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development of FGIDs and particularly IBS, some researchers have coined the name of the 
implicated pathway as ‘microbiota-gut-brain axis’ (34, 35). 
Apart from what is discussed above, there are several additional important factors probably 
playing a key role in the development of IBS such as pain sensation, genetic predisposition, 
gut microbiota, diet and digestive enzyme deficiency, and altered intestinal transit which 
potentially through interactions with each other could result in different FGIDs such as IBS. 
Since my thesis has focused on these factors, I will describe them in more detail. 
1.1.3.1 Pain perception 
Abdominal pain is a major complaint in many diseases including organic and functional 
disorders and is the main symptom in IBS where lack of pain precludes the diagnosis (6). 
However, in recent years and with more knowledge of the unpleasant impact of visceral pain 
on the different life aspects of FGID sufferers, including depression, anxiety (36), sleep 
dysfunction and disturbed QOL (37), researchers are more and more eager to understand the 
underlying causes/stimuli contributing to pain perception in these patients. Abdominal 
visceral pain originates from activation of abdominal nociceptors which can be triggered by 
several stimuli such as inflammation, stretching, immune mediators, ischemia, bacterial 
products and so forth [32]. Having a closer look at these stimuli indicates gut microbiota as a 
key player which could directly or indirectly be involved in the initiation or exacerbation of 
abdominal pain. Probably one of the first studies that demonstrated an association between 
gut microbiota and abdominal pain was a randomized clinical trial which claimed that a 
specific strain of Lactobacillus could relieve pain as well as flatulence in IBS patients (38). In 
the same manner, another study in 2009 exhibited a significant effect for Bacillus coagulants 
GBI-30, 6086 probiotics in relieving the abdominal discomfort and bloating in IBS patients 
(39). The influence of probiotics on diminishing functional abdominal pain has been 
supported by various clinical trials in children as well (40-43). Moreover, in an intriguing 
mouse model study published in 2008, Amaral and his colleagues tried to examine whether 
the presence of microbiota is necessary for the generation of inflammatory pain. Their 
investigation demonstrated that inflammatory pain (inducible by different stimuli such as 
lipopolysaccharide, chemokine, TNF-α, IL-1β and so forth) was reduced in germ-free mice 
(44). Another interesting study in the murine model could support the causative role of 
microbiota in the development of IBS symptoms by revealing that the hypersensitivity to 
colonic distension is transferable from the fecal microbiota of IBS sufferers to the germ-free 
rats (45). Finally, in another study taking advantage of germ-free mice in the assessment of 
visceral hypersensitivity as well as gene expression in the spinal cord, researchers found that 
in the lumbosacral spinal cord of the germ-free mice, expression of TLR1-5,7,9, 12 as well as 
IL-6,10, TNF-α and IL-1(α,β) were significantly increased compared to the controls. In 
addition, germ-free mice compared to control group had increased visceral hypersensitivity at 
the different levels of pressure (46). It could be helpful to remember that FGIDs symptoms 
(mainly abdominal pain and discomfort) are positively associated with visceral 
hypersensitivity (47). It is known that the gut microbiota is able to impact the nervous system 
of the host but exactly how is yet to be clarified. An interesting mechanism has been 
elaborated for this in a key publication in Nature. In this outstanding study in the murine 
model, through different steps, the researchers demonstrated that pain could be induced 
directly by bacteria through activation of sensory neurons which are involved in the 
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modulation of inflammation. In this study, it was shown that pain sensation is associated with 
a load of bacteria and not activation or even presence of the immune system and can take 
place by two alternate pathways. One pathway is related to the binding of a specific pattern 
recognition receptor called FPR1 with bacterial formylpeptide (discovered in Staphylococcus 
aureus) and the other one concerns activation of pore-forming toxin α-hemolysin by 
ADAM10 enzyme which results in rapid calcium flux and subsequently, induction of action 
potentials in the nociceptors (48). Although abdominal pain and visceral hypersensitivity are 
considered among definition criteria and major distinguishing features of IBS (35), their 
association with different etiological factors of IBS could be confounded with numerous 
variables present in the already sufferers of IBS. To have a more solid and clear 
understanding of the existence of any relation or association between these factors such as 
abdominal pain and gut microbiota, it could be helpful to exclude the confounders as much as 
possible. Exploiting general population cohorts instead of case/controls is one means to 
achieve this. However, this kind of data is not easily available and only one study on a small 
sample size of 15 has been published so far. In this longitudinal research (7 weeks follow-up) 
on Finnish healthy individuals, two methods of qPCR and HIT (Human intestinal tract) chip 
were applied to study the gut bacteria as well as archaea. In addition to a significant 
correlation between abdominal pain and bloating with gut microbiota, their intriguing finding 
was the negative correlation observed between abdominal pain and Bifidobacterium (49). We 
also had the opportunity of having access to a well-designed data-enriched cohort, so-called 
PopCol, that is Population-based colonoscopy cohort (described in detail later) and we aimed 
to study the association between abdominal pain and gut microbiota in a bigger sample size 
of the general population. 
1.1.3.2. Altered intestinal transit 
Impaired gut motility is associated with many functional GI symptoms such as bloating and 
distension and is classified among the most important mechanisms implicated in the 
development of IBS (19, 50). In addition, intestinal transit time is considered as a solid and 
objective method to quantify GI functional abnormalities and is used as an endophenotype for 
some functional disorders like IBS (51). Transit time is measured by different methods and 
techniques including radiologic, magnet tracking, and scintigraphic methods, that could be 
costly, invasive and require special equipment (52-54), which turned them into almost useless 
approaches for general population based studies. In 1990, O'Donnell and his colleagues for 
the first time showed that mean stool consistency recorded by patients is in good correlation 
with whole gut transit time (r=-0.77) (55). Thereafter, this association was confirmed by other 
investigations (56, 57) and also stool frequency, another feature of bowel habit, was revealed 
to be correlated with gut transit time, although to a lesser extent (58-61). Therefore, these two 
features turned into reliable surrogate markers for assessment of the colonic transit time. 
Stool consistency is measured by using the Bristol Stool Form Scale (figure 5) which is a 
medical aid to classify the form of feces into seven categories; from type 1 (severe 
constipation) to type 7 (watery diarrhea) (57, 62). Over the years, it has been disclosed that 
gut transit time could be altered by many different factors including food and its features (e.g. 
volume, acidity, osmolarity, fat content, etc.), hormones, medications (such as opioids, 
narcotics, analgesics,  antispasmodics, and prokinetics), severe pain, pregnancy, neuropathies 
such as diabetes-induced neuropathy, body posture and even stress (63-67). 
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Two plexuses of Meisner and Auerbach belonging to and regulated by the enteric and 
autonomic nervous systems, respectively, modulate the motility of the GI tract. The 
autonomic nervous system, in turn, is controlled by different mechanisms including the level 
of serotonin and its receptors and it has been demonstrated that serotonin could directly 
regulate the gut motility (50, 68). Intriguingly, different studies have recently discovered that 
gut microbiota is strongly involved in the regulation of the biosynthesis and concentration of 
serotonin in the gut lumen (69, 70). Nonetheless, this is not the only reason to make 
us believe in the importance of gut microbiota and its probable bidirectional association with 
gut motility. Many years ago, the observation of up to 10 times larger cecum in germ-free rats 
compared to conventional rats in addition to delayed gastric emptying in them suggested a 
strong role for the microbiota in the development of normal gut motility (71-74). 
Furthermore, these findings were consolidated when conventionalized germ-free animals, 
restored their physical function (75, 76). On the other hand, it is believed that a healthy gut 
motility, in turn, could exclude the pathogenic microorganisms and contribute to the 
formation of a healthy gut microbiota(77). 
In 2008, an interesting publication 
from Jeffrey Gordon’s lab 
revealed that gut microbiota 
through short-chain fatty acids 
(SCFAs) and one of their 
receptors (Gpr41) can modulate 
gut motility and change intestinal 
transit rate (78). Later on, in 
2013, a paper from the Bäckhed 
lab suggested another mechanism 
for modulation of the intestinal 
transit time by gut microbiota. 
They showed that increased level 
of GLP1 in the animal model 
could result in a slower transit 
time. GLP1 is a hormone which is 
regulated by SCFAs produced by 
the gut microbiota (79). On the 
other hand, very recently, Vandeputte et al. hypothesized that faster transit rate contributes 
to variation in the colon ecosystem. To investigate that, they applied BSFS as a surrogate 
for transit time and studied it in association to different markers of microbiota composition 
in 53 healthy women. They found that stool consistency is strongly associated with 
microbial richness, i.e. looser stool was associated with fewer observed species and Chao1 
(two parameters of richness). Moreover, looking at each individual’s microbiota growth 
potential, they found that shorter transit time is probably linked to the higher abundances of 
fast-growing species (80). Part of these results were replicated in another study by 
Tigchelaar et al. which was done on a bigger sample size (n=1126) and in both men and 
women using averaged 7-day records of BSFS as the measurement for transit time (81). 
However, stool frequency, as another surrogate index for colonic transit time had not yet 
been investigated in relation to microbiota composition. We hypothesized that there is an 
Bristol stool scale 
Figure 5. Bristol stool chart.  
Photo from Wikipedia, labeled for reuse. 
Type 1  Separate hard lumps 
Type 2  Sausage-shaped and lumpy 
Type 3  Sausage-shaped with cracks on 
the surface 
Type 4  Like a soft sausage or snake 
Type 5  Soft blobs with clear-cut edges 
Type 6  Mushy stool with ragged edges 
Type 7 Watery stool with no solid pieces 
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association between gut microbiota and stool frequency and were enthusiastic to examine it 
in the PopCol cohort. 
Surprisingly, another very important factor that potentially shapes and regulates all the 
structures and functions of the body, genetics, had not yet been investigated well here. 
Although limited numbers of genotype analysis have nominated a few genes associated 
with gut transit time (51, 82, 83) and defecation (84), no hypothesis-free genetic study had 
yet been accomplished. Regarding the significance of the impaired gut motility in the 
development of gut symptoms, a genome-wide study approach for hunting the genes or loci 
which are associated with the regulation of transit time could be of great importance for 
understanding the underlying pathogenesis of bowel functional disease and optimistically 
finding new treatments for them (83). Therefore, we aimed to undertake a genome-wide 
association analysis to study one of the surrogate markers of transit time, stool frequency, 
in two well-characterized population-based cohorts. 
 
1.1.3.3 Genetic predisposition 
For the first time in 1998 in a twin study from the Australian Twin Registry, it was 
suggested that genetics could substantially contribute to the development of functional 
bowel disorders (85). Shortly after that, different twin studies were performed to investigate 
the heritability component of FBDs and particularly IBS (86-89). Although these studies 
overall supported the idea of the existence of a genetic predisposition for IBS, the results 
were somehow conflicting (90). However, all of these studies have been conducted on first-
degree kins and spouses (to distinguish between the effects of environment and genetics in 
adults), except for a prominent study from Sweden published in 2015. In this investigation, 
first-, second- and third-degree relatives, as well as spouses, were taken into consideration 
for the calculation of the odds ratio for IBS development. In this study, they observed that 
the risk of IBS is significantly higher in all the relatives (the closer, the higher) as well as in 
spouses and concluded that both genetic and environmental factors are important in the 
development of IBS (91). Becoming aware of the importance of a genetic background in 
IBS generation, the next step would be the identification of the involved genes and 
pathways. Thus far, no unequivocal IBS risk gene has been recognized and the genetic 
studies are limited to one original genome-wide assocaition study (GWAS) paper and 
mostly underpowered, candidate-gene investigations.  
IBS, similar to many other common diseases (e.g. hypertension, diabetes, obesity and so 
forth), is considered a ‘complex genetic disorder’, that is a multifactorial genetic disorder in 
which many genes and genetic variants are involved in its development, each with a small 
contribution to the increase of the risk. These categories of disease are still considered as 
heritable and like what we see in IBS they aggregate more in some families but most of the 
time we cannot see the Mendelian pattern of transmission in the families (92). However, 
there might be a few exceptions and we could probably discover some highly penetrant 
genetic variants which could be mainly implicated as the cause of the disease in a subset of 
the patients. This is of great importance because it could potentially result in stratification 
of patients based on their genetic predisposing factor and one could then take advantage of 
individualized medicine for them. One good example for this is the specific mutation 
discovered in the SCN5A gene (a sodium ion channel gene) through collaboration between 
Mayo Clinic and our lab from Karolinska Institute. This gene (shown to explain the 
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symptoms in more than 2% of mainly IBS-C cases) is potentially involved in gut motility. 
Interestingly, Mexiletine, a medication effective for the improvement of the sodium channel 
defects, could ameliorate the symptoms in a patient with severe IBS-C carrying a loss-of-
function mutation (82). In addition to the 10 deleterious mutations in this gene, a few 
common SCN5A variants (single nucleotide polymorphisms (SNPs)) showed association 
with IBS risk in the only IBS GWAS published so far with a decent samples size (described 
later) as well (93).  
Therefore, to have a comprehensive understanding of the genetic background of the 
complex disease like IBS, a combination of different approaches such as family-based 
studies, hypothesis-free GWA studies, candidate gene approaches and eventually fine-
mapping sequencing studies could be helpful.  
However, evidently, compared to other complex diseases, less effort has been made in the 
discovery of the genetic background of IBS thus far and most of these efforts have been 
limited to candidate gene studies conducted in small case-control cohorts (8). In addition, 
most of the genes with suggestive mechanisms in the development of IBS, are not 
replicated and validated by other studies, except for a few genes like TNSFS15 which has 
been constantly shown to be associated with IBS in several studies from different countries 
(Sweden/US (94), Canada (95), and the UK (96)). A selection of the genes suggested to 
play a role in the generation of IBS in different studies, has been gathered in table 1. It 
should be noted that each of these genes is implicated in the development of the disease in 
merely 1-5% of sufferers and according to the definition of common variants, they have 
only a small contribution (97). Unsurprisingly, genes related to the serotonin pathways are 
among the most common investigated/proposed genes related to IBS pathophysiology, 
which could possibly be related to the renowned gut–brain pathway (51, 98). 
As was mentioned earlier, also one original GWAS paper has been published so far. Except 
for that, only one pilot study exploiting a small sample size (n(case): 172, n(control): 
almost 1400) from an Australian cohort has been published. In that study two genome-wide 
significant loci on chromosomes 4 and 10 including one and four genes respectively, were 
identified (99).  
The more comprehensive GWAS included 534 IBS cases and close to 5000 controls from a 
Swedish general population cohort. Subsequently, suggestive-threshold significant results 
were replicated in a total sample of 1793/1718 (cases/controls) from cohorts of Sweden, 
Belgium, Italy, Germany, Greece and the USA followed by a meta-analysis. Intriguingly, 
one locus on chromosome 7 including the two genes KDELR2 and GRID2IP were shown to 
be associated with IBS in the GWAS (suggestive threshold) as well as in the replication 
study and meta-analysis. Furthermore, GWAS results were screened for the previously 
reported IBS risk genes. Out of 31 studied genes, 16 were shown to be nominally 
significant with the most convincing results for IL1R1 and SCN5A respectively. TNSFS15 
was also shown to be nominally significant in this GWA study, although the p-value was 
not so strong (p=0.046) (93). Given the promising results regarding SCN5A, 
channelopathies could be considered as potential underlying abnormalities in IBS. To test 
this hypothesis, 27 genes coding for various GI-related ion channels were selected from this 
GWA study accomplished in our lab. Our aim then was to further investigate the 
involvement of these ion channel genes in IBS. 
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Table 1. Selection of the genes suggested to play a role in the generation of IBS in the different 
studies 
 
Gene name Gene function IBS type Ref 
ADRA2A Adrenergic pathway  IBS-C, IBS-D 
(100, 
101) 
ADRA2C Adrenergic pathway  IBS-C (100) 
BDNF Psychiatric  IBS (92) 
CCK1R Gastrointestinal transit IBS-C/ IBS-M 
(102, 
103) 
CCK2R Gastrointestinal transit 
IBS-C (only in 
women) 
(102) 
CDC42 
Cell cycle regulation and likely epithelial barrier 
function  
IBS-C (96) 
CNR1 Psychiatric genes (endocannabinoid system) IBS (104) 
COMT Psychiatric  IBS-C (92) 
DDC Serotonin pathway IBS-C, IBS-M 
(92, 
105) 
FAAH 
(C385A) 
Gastrointestinal transit IBS-D, IBS-M (106) 
FGF2 Inflammatory/Immune pathway genes IBS (99) 
FGFR4 Gastrointestinal transit IBS-D (107) 
GNβ3 Inflammatory/Immune pathway genes IBS 
(108, 
109) 
GPBAR1  
Accelerated colonic transit possibly through 
impaired bile acid metabolism and function 
IBS 
(110) 
 
GRID2IP 
Gastrointestinal transit and host-microbiota 
interactions 
IBS (93) 
HTR2A  Serotonin pathway genes IBS-D 
(92, 
105) 
HTR3A Serotonin pathway genes IBS-D 
(92, 
105, 
111) 
HTR3B Serotonin pathway genes IBS 
(92, 
105) 
HTR3C Serotonin pathway genes IBS-D 
(92, 
105) 
HTR3E Serotonin pathway genes IBS-D 
(92, 
105) 
HTR4 Serotonin pathway genes IBS-D, IBS-C 
(92, 
105) 
HTR7 Serotonin pathway genes IBS-C 
(92, 
105) 
IL1R Inflammatory/Immune pathway genes IBS (112) 
IL4 Inflammatory/Immune pathway genes IBS (113) 
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IL6 Inflammatory/Immune pathway genes PI-IBS, IBS 
(112, 
114) 
IL8  Inflammatory/Immune pathway genes IBS (115) 
IL10 Inflammatory/Immune pathway genes IBS 
(115-
117)  
KDELR2 
Mediates the retrograde transportation of the 
proteins to the endoplasmic reticulum 
IBS (93) 
KLB 
Colon transit time (possibly through impaired 
bile acid metabolism and function) 
IBS-D (107) 
NUDT6 Inflammatory/Immune pathway genes IBS (99) 
NXPH1  Unknown mechanisms  IBS-D (96) 
NPSR1 
Is candidate to be associated with IBS through 
two mechanisms of  altered colonic transit 
and/or epithelial barrier dysfunction 
IBS 
(51, 
118) 
PRDM1  Barrier function and permeability IBS-D (119) 
PCDH15 Barrier function and permeability  IBS (99) 
SCN5A Voltage-gated sodium channel  
IBS  (mainly 
IBS-C) 
(82) 
SLC6A4 
(5-HTTLPR)  
Serotonin pathway genes IBS-C 
(100, 
109) 
TDO2 Serotonin pathway genes IBS 
(92, 
105) 
TLR9 Inflammatory/Immune pathway genes PI-IBS (120) 
TNFa Inflammatory/Immune pathway genes IBS 
(112, 
117) 
TNFSF15  Altered immune function 
IBS, IBS-C,   
IBS-D, IBS-A 
(94-
96) 
TPH1 Serotonin pathway genes IBS-D (121) 
TPH2 Serotonin pathway genes IBS-M 
(92, 
105) 
IBS-A: IBS with alternating constipation and diarrhea, IBS-C: Constipation-predominant IBS, IBS-D: 
Diarrhea-predominant IBS, IBS-M: Mixed IBS, PI-IBS: Post-infectious IBS. 
 
1.1.3.4 Diet/digestive enzyme deficiency 
Diet is probably the most well-known contributing factor to IBS which is mainly reported by 
the patients. Many IBS sufferers have a list of foods which they believe exacerbate their 
symptoms, and therefore often try to avoid them (122, 123). 
FODMAPs, which stands for ‘fermentable oligo-, di-, and monosaccharides and polyols’, are 
good examples repetitively identified as possible triggers for the IBS symptom development. 
FODMAPs are short-chain carbohydrates that, if not properly digested and absorbed, can 
induce accumulation of excessive luminal fluid due to their osmotic activity, and are also 
rapidly fermented by gas-producing colonic bacteria. This can together lead to IBS symptoms 
including distention, bloating and abdominal pain. FODMAPs exist in various foods and 
trigger symptoms in a subset of people while most people can tolerate them well. Different 
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factors are implicated in the symptom generation by FODMAPs including the absence or 
deficiency of the luminal or brush border enzymes, absence or hypoactivity of the epithelial 
transporters, dysbiosis and altered fermentation rate (124, 125).  
Lactose intolerance classified in ‘IBS-like disorders’ is one example of a brush border 
enzyme (lactase) deficiency which is characterized by diarrhea, flatus, abdominal pain and 
distension. Lactase persistence (persistence of the lactase activity after the weaning phase) is 
dominantly inherited and has a strong genetic background. However, in addition to the 
expression level of lactase, other factors such as gut microbiota, GI motility and the level of 
GI tract sensitivity to the gas accumulation play important roles in the induction of the IBS-
like symptoms (126, 127).  
Sucrase-isomaltase (SI) is another intestinal brush border enzyme which is key to the 
degradation of the daily digested sugars (sucrose) and starch (128) and its deficiency could 
cause the accumulation of unabsorbed carbohydrates in the colon leading to a variety of 
symptoms commonly reported by IBS-D patients (abdominal pain, bloating, and osmotic 
diarrhea). CSID (congenital sucrase-isomaltase deficiency) is the congenital form of SI 
deficiency and is generated due to the harboring of two defective alleles of the gene which 
results in a serious reduction of the enzyme activity or even a complete abolishment of it 
(129, 130). However, although CSID is usually diagnosed in infancy, there are reports of 
diagnosis in adults who have been misdiagnosed with IBS due to the milder symptoms (131, 
132). Therefore, it could be speculated that alterations in the enzyme activity secondary to the 
milder (heterozygotic) functional genetic variations could contribute to IBS predisposition. In 
paper V, through a series of independent experiments, we test the potential relevance of SI 
gene variants for IBS, stool frequency, and gut microbiota composition. 
1.1.3.5 Gut Microbiota 
A major focus of my Ph.D. project was the gut microbiota. So herein I will discuss it in more 
detail. 
Human individuals are born with a few passive mother-to-child transferred bacteria which co-
develop with them from birth until death (133). The human gut microbiota is a very complex 
ecosystem, which has co-evolved with the host and imparts immense effects on her/his 
physiology. This effect is so large that it has been postulated that there are several axes in the 
body in which the gut microbiota is at one end, including gut-liver axis (134), gut-immune 
system axis (135), gut-heart axis (136), gut-muscle axis (137) gut-brain axis (138, 139) and 
even gut-renal axis (140, 141). For decades, it was believed that the human gut microbiota 
outnumbers the host cells by 10 fold. However, recently it has been shown that this was due 
to a misestimation of the body’s cell number as well as the volume of the colon and therefore 
the correct ratio seems to be 3.8 to 3 (bacteria to human cells) which is still remarkable 
because it means that we are more bacteria (56%) than human! (142, 143) (figure 6). In the 
same manner, the total weight of the bacteria living in and on the human body is estimated to 
be 200 gr (it was miscalculated as 2 kg before). However, although the gene number of the 
microbiota has been estimated/calculated differently in different attempts (144, 145), it seems 
that microbial gene content outnumbers the human genes by a factor of 100 (at least) which  
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led to the coining of the term ‘the second human genome’ (146). Nevertheless, it is very 
important to note that unlike our own genome, our microbiome (all microbes and their genes 
(147)) is possible to be re-shaped or even cultivated (138, 139) which could be considered as 
a big opportunity for future medical interventions. Another interesting aspect that should be 
taken into consideration is that although we, as humans, are very similar to each other 
regarding our genome (almost 99.9% similarity) our microbiomes are very different (roughly 
10% similarity) (148) which could be a positive point regarding individualized medicine. 
Noteworthy, the human microbiota encompasses bacteria, as well as, archaea, eukaryotes 
(mainly yeasts) and viruses (mainly phages) but since bacteria prodigiously outnumber the 
other domains, scientists sometimes refer to the whole microbiota as the bacteria. Obviously 
this amount of bacteria is not distributed equally over the GI tract and regardless of the mouth 
which is considered as the second dirtiest place in the body, there is a density gradient for 
bacteria from the stomach to the anus (figure 7) (142). Therefore, when we talk about the gut 
microbiota we mostly refer to the bacteria colonizing our colon. In 2011, Arumugam and 
Raes introduced a new concept to the world of microbiota, i.e. enterotype. Deep profiling of 
metagenomics fecal sample data from 39 healthy individuals revealed that human gut 
microbiota can be clustered into three discrete groups which were dominated by Bacteroides, 
Ruminococcus and Prevotella respectively (149). However, these enterotypes could not be 
replicated in all subsequent studies which different methodological factors including 
clustering approaches, operational taxonomic unit (OTU)-picking methods, read depth and 
16S rRNA primers could be the explanation (150). Moreover, some studies even have 
claimed that enterotype distribution is spectrum-wise and there is a gradient instead of 
discrete groups similar to blood groups (151).  
Figure 6. The ratio between number of human cells to the number of gut microbiota (left) and the 
number of human genes to the number of gut microbial genes (right).  
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Until a couple of years ago, the gut microbiota was considered as a forgotten organ (152) but 
nowadays its importance is so obvious that scientists have started to call it the second brain of 
the human (138, 139), the second liver (153) and as mentioned before the second genome 
(146). Gut microbiota’s impacts on the host body can be categorized into two different 
classes of beneficial effects which arise from the healthy gut microbiota and the harmful 
effects which are secondary to the dysbiosis. Achieving a better comprehension of a ‘healthy 
gut microbiota’ could be the first step in better understanding of the substantial effects of gut 
microbiota on host health. 
I. Healthy gut microbiota 
A literature review shows that there is no unique consensus definition for a ‘healthy gut’ yet. 
The European metagenomics of the human intestinal tract (MetaHIT)  as well as the human 
microbiome project (HMP) from the US are among the first large-scale sequencing projects 
(n=124, and 242, respectively) accomplished to describe the healthy gut’s as well as other 
organ’s microbiota (figure 8). 
Figure 7. Bacterial density in each section of GI tract, calculated based on the concentration of 
bacteria and volume (Sender, revised, 2016). 
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However, these remarkable studies followed 
by considerable amounts of other 
investigations indicated that the microbiota 
composition is very complex and varies 
significantly between and even within 
individuals (over time). Noteworthy, it has 
been known that each individual is colonized 
by more than 1,000 species which obviously 
originate from only a few phyla. However, 
although almost all the studies have a 
consensus over the two major bacterial phyla 
being Firmicutes and Bacteroidetes (154, 
155) a Dutch cohort, called LifeLines-DEEP 
(n=1135), showed that agreement even over 
this level of information is not easily 
achievable by revealing Firmicutes and 
Actinobacteria as the two dominant phyla in 
the study participants (156). 
Intriguingly, a Cell publication in 2013, has 
indicated that the functionally active part of 
the gut microbiota is predominant in 
Firmicutes and depleted in Bacteroidetes, so it 
could be concluded that the Firmicutes 
phylum is the functional subset of the gut 
microbiota although Bacteroidetes is usually 
the more abundant phylum (157, 158). In 
addition to the number of different bacteria that harbor our gut, how evenly they are 
distributed, how phylogenetically close they are, how many genes they have and how many 
of them are active in the body, are other very important factors that should be taken into 
consideration (155). In general, it seems that high diversity, more stability and probably a 
decent ratio between so-called good and bad bacteria (such as Faecalibacterium prausnitzii 
and Roseburia versus Escherichia and Fusobacterium), are among a few facts that we know 
so far about a healthy gut microbiota. 
Having proven the high variability of the healthy gut microbiota, the next step would be to 
understand the physiological factors contributing to program this normal variation as well as 
the factors potentially able to disturb it and push it towards dysbiosis. 
I.I. Intrinsic host factors 
Age. Before delivery, during it and immediately afterward, the infant’s GI tract is colonized 
by a low diversity microbiota originating from mother, diet, and environment (133, 159). 
When starting the solid food, the gut is gradually inhabited with more diverse microbiota and 
when established (from around 18 months to three years old), this compositional structure 
remains highly resilient (although one study has shown that adolescent’s gut microbiota 
differs from adults’ (160)). Again in elderly (after 70) the diversity decreases. These age 
Figure 8. Different phyla inhabiting different 
body sites. Reprinted from Advances in 
Medical Sciences, 62/2, Blum HE, The human 
microbiome, Pages No. 414–420, Copyright 
(2017), with permission from Elsevier. 
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categories have been shown to be accompanied by changes in the ratio between Firmicutes 
and Bacteroidetes being 0.4, 10.9 and 0.6 for infants, adults and elderly subjects, respectively 
(161). However, another interesting study performed on three groups of people aged 99 to 
104 years (centenarians), 63 to 76 years and 25 to 40 years, revealed that only in centenarians 
was the gut microbiota altered significantly but the composition in young adults and seventy-
year-old people was quite similar (162). Moreover, age has been recorded as being among the 
18 non-redundant variables associated with microbiota composition that resulted from one of 
the most comprehensive analyses carried out so far (163) and this result has been confirmed 
by another general population-based important study in the field (156). Finally, in a key study 
investigating the different genetic and non-genetic factors involved in the shaping of gut 
microbiota structure, age was revealed to be responsible for almost 5% of all the variations 
(164).  
Gender. For years, although gender was usually considered among the covariates in 
microbiota studies, there was not a solid scientific background for this. In an investigation of 
subjects from four countries of France, Germany, Italy, and Sweden in 2006, a gender effect 
was only reported for a specific bacterial group (165). Another study in five northern 
European countries, could not find any grouping for colonic microbiota according to the 
gender of the hosts (166). However, in an attempt to investigate the association between 
obesity as a function of gender with gut microbiota composition, Haro et al. observed that gut 
microbiota probably is different between the genders (167). Almost reassuringly, this finding 
was confirmed by two recent Science publications (156, 163). More interestingly, in 
Zhernakova’s paper, gender, as well as age, was shown to be correlated with microbial 
functional richness in addition to the composition and diversity (156). Also, in the Wang et 
al. study sex was shown to be responsible for close to 2% of the variation in the gut 
microbiota composition (164). 
Fecal chromogranin A (CgA). CgA is another factor recently shown to be negatively 
associated with gut microbiota composition (156). CgA is secreted from neurons, the 
endocrine system and immune cells (under stress) and is considered as an indicator for the 
activation of the neuroendocrine system. Interestingly, in this study, 126 host factors 
(intrinsic and extrinsic) have been studied and CgA demonstrated the strongest association 
with different microbial indices including several taxa in which their total abundances 
account for more than 50% of the gut microbial composition. However, it should be noted 
that in the same study, CgA was shown to be negatively associated with the amount of fruit 
and vegetable intake in the studied population so any conclusion should be made with 
caution. 
Genes. From the very beginning of the 20th century, twin studies suggested a heritable origin 
for microbiota, indicating that host genetics could play an essential role in the formation of 
the gut microbiota composition (168). Since then, additional heritability studies, as well as 
candidate gene studies in both murine models and human settings, have supported this 
hypothesis. A selection of heritability studies and candidate gene studies are summarized in 
tables 2 and 3. Finally, very recently a few well- designed GWAS have confirmed this (table 
4).  
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Table 2. Selection of the microbiota heritability studies. 
DZt: Dizygotic twins, MZt: Monozygotic twins, m: months, y: years old. 
  
Study Sample  Sequencing method Results 
Zoetendal 
et al. 
(2001) 
(168) 
50 adults younger 
than 60 y 
(genetically 
related people 
were living 
separately) 
Denaturing 
gradient gel 
electrophoresis  
Fecal microbiota profiles of MZt 
were more similar compared to 
unrelated people. Bacterial profiles 
of spouses were not significantly 
more similar than unrelated 
individuals. 
The more genetically related, the 
more similar bacterial profile.   
Stewart et 
al. (2005) 
(169) 
13 MZt, 7 DZt 
and 12 unrelated 
control pairs. 
median age: 23 m 
(4 m to 10 y) 
Temporal 
temperature 
gradient gel 
electrophoresis  
Fecal profiles of the MZt showed the 
highest level of similarity in addition 
to the significant difference with DZt 
and controls. 
Turnbaugh 
et al. 
(2009) 
(170) 
31 MZt and 23 
DZt (21–32 y/ all 
females and 
concordant 
for BMI) and 46 
of their mothers 
(where available)  
16S rRNA 
sequencing (gene’s 
full-length) plus 
pyrosequencing 
(V2 and V6) 
Gut microbiota of MZt was not 
significantly more similar than DZt. 
People from the same family shared 
a more similar bacterial profile 
compared to unrelated individuals 
(not correlated with the physical 
living distances).  
Goodrich et 
al. (2014) 
(171) 
171 MZt, 245 
DZt, 2 unknown 
zygosities, 143 
single individuals 
from a twin (20 
men, the rest 
women) from 
TwinsUK registry 
16S rRNA (V4) Fecal microbiota was more similar 
within twin pairs than controls. 
Comparing MZt and DZt, MZt had 
more similar microbiota only when 
testing unweighted Unifrac. About 
5% of the taxa were shown to have 
heritability and Christensenellaceae, 
a family associated with low BMI, 
was the most heritable taxon. 
Goodrich et 
al. (2016) 
(172) 
472 MZt and 418 
DZt from 
TwinsUK registry 
16S rRNA (V4) They expanded their initial twin 
study and detected 8.8% of the taxa 
to be heritable.  
Xie et al. 
(2016) 
(173) 
69 MZt and 181 
DZt females from 
TwinsUK registry 
Whole-
metagenome 
shotgun 
sequencing 
In addition to supporting many of the 
previous results, they inferred that 
the high similarity in microbiome 
variations within twins reduces 
slowly over years of separate living. 
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Table 3. Selection of the microbiota candidate gene studies
*
. 
Gene name Gene function Description 
Nucleotide-
binding, 
oligomerization 
domain 2 
(NOD2) 
Mediates the 
host response to 
the bacterial 
peptidoglycan 
and is implicated 
in susceptibility 
to the Crohn's 
disease. 
 In one study in Nod2-deficient mice, the load of 
commensal bacteria was increased in these mice while 
their ability to prevent their GI tract from colonization by 
pathogenic bacteria was decreased (174).  
 Another murine model study in addition to supporting 
these results indicated the substantial influence of nod2 
on the early development of the intestinal microbiota in 
Crohn's disease (CD) patients (175). 
 In a cross-sectional analysis of the human mucosal 
(ileal) samples, NOD2 genotype (and IBD phenotype) 
was linked to a shift in the relative abundance of the 
Clostridium coccoides and Eubacterium rectale groups 
(176). 
 A significant association between an increase in the 
relative abundance of Enterobacteriaceae and NOD2 risk 
allele counts was demonstrated in an investigation on 474 
individuals from three independent cohorts (151). 
Fucosyltransfe
rase 2 (FUT2) 
Is responsible 
for the presence 
of ABO histo-
blood group 
antigens found 
on the GI 
mucosa and 
secretions 
 Comparing the healthy subjects and CD patients 
revealed that FUT2 genotype can explain some differences 
in the composition and diversity of the gut microbiota 
(177). 
 Two years later these results were replicated in another 
study using mouse model and it was shown that microbial 
diversity of Fut2
−
 mice is diminished (76). 
 An investigation on 14 non-secretor and 57 secretor 
adult humans, confirmed the previous results by 
demonstrating lower species richness in non-secretors 
compared to the secretors (178).  
 Study on 35 healthy individuals including 27 secretors 
and 6 non-secretors, supported the hypothesis of 
significant difference between bacterial taxa of secretors 
and not secretors. However, in this study non-secretors 
had higher α-diversity at the taxonomic higher levels of 
phylum, class, and order. Also, this study claimed a bigger 
effect for being non-secretor compared to blood groups 
(179). 
Human 
leukocyte 
antigen (HLA)-
DQ 
Recognizes and 
presents foreign 
antigens to the 
immune cells 
and its mutations 
predisposed the 
carrier to the 
Coeliac disease 
(CoD) 
 A study on 20 newborns whom at least one of the first-
degree relatives suffered from CoD, showed that this gene 
can influence the gut microbiota composition by inducing 
changes in the abundances of different bacteria (180). 
 Those results were supported by another study which in 
addition, demonstrated that high genetic risk of suffering 
from CoD is accompanied by considerably higher 
proportions of Firmicutes and Proteobacteria and lower 
abundances of Actinobacteria (181). 
Immunity-
related GTPase 
M (IRGM) 
Involved in the 
regulation of 
autophagy 
This gene which is among a few genes recognized to 
affect gut microbiota composition in the healthy 
population is the only one shown to be associated with the 
presence of an enterotype (Prevotella-predominant 
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enterotype) (182). 
lactase (LCT) Translates to the 
lactase (an 
enzyme for 
hydrolyzing 
lactose in the GI 
tract)  
 
 In one of the first microbiota-GWA studies (n=93), this 
gene was shown to be associated with the GI abundances 
of Bifidobacterium (183).   
This interesting result has been supported by another 
investigation on 1,126 twin pairs (172) and two other big 
GWA studies (164, 184), in one at the genome-wide 
significance threshold level (184). 
*There are other genes that have been shown to be involved in the formation of gut microbiota 
composition. Among them, one can refer to IgA (185), MEFV (186), NLRP6 (187), ABO (188), 
RELMβ (189), and DEFA5 (190) which except for ABO and RELMβ, all are involved in the immune 
system related functions. 
CD: Crohn's disease, CoD: Coeliac disease. 
 
Table 4. Microbiota genome-wide association studies (GWAS). 
Study Sample 
Sequencing 
method 
Results 
Benson et 
al. (2010) 
(191) 
645 mice 16S rRNA  
(V1-V2) 
64 core measurable microbiotas were 
studied in association to 530 SNPs. This 
study revealed 18 host-associated QTLs 
(quantitative trait loci) correlated with the 
abundances of some specific microbiota. It 
also revealed that the gut microbiota 
composition could be a polygenic trait. 
Moreover, some of the QTLs showed 
pleiotropic effects on the microbiota 
signature. They also reported phyla of 
Actinobacteria, Erysipilotrichi, and 
Epsilon to be QTL associated. 
Blekhman 
et al. 
(2015) 
(183) 
Discovery 
cohort: 93 
from HMP 
Replication: 
984 from the 
TwinsUK   
Whole-genome 
sequencing 
In this study, 83 significant associations 
were reported (at the suggestive 
significance threshold of 1.16E-5).  
A significant association between the first 
stool microbiome principal coordinate and 
host genetic principal component was 
reported. An SNP in LCT gene was shown 
to be linked to the Bifidobacterium 
abundance. 
Davenport 
et al. 
(2015) 
(192) 
91 and 93 
(summer and 
winter, 
respectively) 
from 
Hutterites 
16S rRNA (V4) α-diversity and bacterial relative 
abundance were studied in this GWAS. 
Running a classic GWA analysis and 
applying the genome-wide significance 
threshold, they did not find any significant 
result. But changing the significance level 
(q-value=0.2), at least in each sample, one 
bacteria was shown to be significantly 
associated with at least one SNP. 
Akkermansia (previously shown to be 
obesity-related) was associated with an 
SNP close to PLD1 gene (also shown to 
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be associated with BMI). Performing gene 
set enrichment analysis (GSEA), they 
found some pathways including immune 
processes related to summer samples and 
metabolic processes enriched in winter 
samples.  
Goodrich 
et al. 
(2016) 
(172) 
1126 
including 
472 MZt 
and 418 DZt 
from 
TwinsUK  
16S rRNA (V4) Bacterial taxa and β-diversity indices were 
investigated as the study traits. No study-
wide significant signal was detected. 
Testing the taxa level, 28 loci, and 
studying β-diversity indices, 3 loci showed 
genome-wide significant (GWS) 
associations.    
Strongest associations were reported for 
the gene SLIT3 with the taxa unclassified 
Clostridiaceae. Also, LCT gene was 
revealed to be in strong linkage 
disequilibrium (LD) with the gene 
R3HDM1 (including a SNP with the 
strongest association with 
Bifidobacterium). 
Wang et 
al. (2016) 
(164) 
Discovery 
cohort: 
1,812 
individuals 
from two 
German 
cohorts 
Replication: 
371 German 
individuals 
16S rRNA 
(V1-V2) 
In this study bacterial taxa and β diversity 
indices were studied. Investigating β-
diversity measures (PCoA based on Bray-
Curtis and Jaccard), and bacterial taxa, 42 
and 40 GWS associated loci respectively 
were reported. Among them, the most 
interesting result was related to the locus 
including VDR gene which encodes 
vitamin D receptor. This gene was 
significantly associated with β-diversity 
indices as well and vitamin D response 
appeared in the results of the GSE 
analysis.  
In this study, the results for three genes of 
FUT2, NOD2, and LCT were replicated 
too. 
Also, they indicated that genetic factors 
account for roughly 10% of the gut 
microbiota variations (almost equal to all 
known non-genetic factors). 
Bonder et 
al. (2016) 
(184)  
Discovery 
cohort: 984  
Replication: 
530 Dutch 
individuals  
Whole genome 
sequencing 
In addition to bacterial taxa, functional 
gene categories and bacterial pathways 
were studied. In this study, 9 GWS 
associated loci were detected in relation to 
8 taxa of which the most significant 
associations were reported with genus 
Blautia and Species Bacteroides 
xylanisolvens (Blautia has shown 
heritability in the Goodrich et al. study 
(2016) too). Moreover, 33 GWS loci in 
association with the other two traits were 
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reported, without any overlap with the 
results from bacterial taxa. Also, in 
addition to the replication of the 
association between LCT and 
Bifidobacterium, they suggested that an 
interaction between a specific genotype 
and milk consumption could play a role in 
the determination of the Bifidobacterium 
abundance.  
Turpin et 
al. (2016) 
(193) 
Discovery 
cohort: 1098 
Replication:  
463 (from 
US and 
Israel) 
16S rRNA (V4) α-diversity, microbial dysbiosis index 
(MDI) and bacterial taxa were three study 
traits. They could not find any GWS 
association for either α-diversity or MDI. 
However, 58 loci significantly associated 
with bacterial taxa, of which 6 remained 
significant after multiple test correction. 
Also, they could replicate the association 
of 4 loci (containing UBR3, CNTN6, 
DMRTB1 and SALL3 genes) with 
Rikenellaceae, Faecalibacterium, 
Lachnospira, and Eubacterium, 
respectively, in the replications.  
DZt: Dizygotic twins, LCT: Lactase, LD: Linkage disequilibrium, MDI: Microbial dysbiosis index, 
MZt: Monozygotic twins, PCoA: Principal coordinate analysis, GSEA: gene set enrichment analysis, 
GWAS: genome-wide association study, GWS: Genome-wide significant. 
 
Although at least the last four GWAS have exploited decent sample sizes, surprisingly most 
of the signals were only reported in one study and very few overlaps are detectable between 
the results (194)(the best result we have so far is the signal related to the LCT gene which has 
constantly been shown to be associated with Bifidobacterium). This observation has been 
linked to the high complexity of the trait. It means that a large number of genes and loci are 
involved in the formation of the trait and each gene/locus contributes to a very small fraction 
of the variations (according to the definition of complex genetic traits) which makes it very 
difficult for it to be identified or replicated in different studies (195). Moreover, when the 
effect sizes are very small, differences in methodology and experimental protocols applied in 
the different studies could easily outweigh the underlying effects. In one study from the Rob 
Knight lab, it was observed that individuals from different microbiota study cohorts, 
primarily clustered by the studies which showed that any difference in the study methods 
including primer selection for 16S studies, DNA extraction techniques (one of the largest 
sources of bias (196)), sequencing platform, and bioinformatics pipelines could introduce 
systematic biases into these studies (197). 
I.II. Extrinsic host factors 
I.II.I. Mother induced 
-Method of delivery. Infants born through natural vaginal delivery within a few days after 
birth are mainly colonized by microbiota which is similar to their mothers’ vaginal microbes 
(mainly Lactobacillus, Prevotella, or Sneathia spp.). However, gut microbiota of infants born 
through cesarean section (CS) more resembles the commensal skin bacteria (dominated by 
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Corynebacterium, Staphylococcus, and Propionibacterium spp.) (198). An interesting study 
which followed vaginally and CS delivered babies for two years, revealed that microbial 
diversity of CS born children was significantly diminished. Moreover, the abundance and 
diversity of Bacteroidetes phylum were lower in these children compared to vaginally 
delivered babies (199). However, the long-term effect of the delivery method is not supported 
by adult studies and is not clear yet (154). It is worth mentioning that gut microbiota of 
pregnant mothers alters from the first trimester to the third. The first-trimester microbiota is 
quite similar to non-pregnant women but the third-trimester microbiota has less 
Faecalibacterium (butyrate producer with anti-inflammatory effects) and more 
Proteobacteria and Actinobacteria and shows decreased richness which is strongly correlated 
with inflammation and energy loss. However, interestingly, the children’s microbiota 
composition is more similar to the microbiota composition of mothers in the first trimester 
(200).  
- Method of infant feeding. Mothers’ breast milk contains particular oligosaccharides 
including indigestible sugars which are completely unique to humans and can be directly 
consumed by the infant’s gut microbiota (mainly Bifidobacterium and also Bacteroides). 
During the breastfeeding process, the type and amount of the carbohydrate content of the 
breast milk changes which could be reflected in the alterations of the gut microbiota 
composition (154, 201). 
In summary, breastfeeding in contrast to formula has been shown to affect gut microbiota in 
at least three ways: 
1. Breast milk includes viable bacteria (102 to 104 per ml), which means at least 105 bacteria 
per day for exclusively breastfed infants. Hence, breast milk, on its own, can be considered 
as a probiotic (202, 203).  
2. Breast milk can be considered as a prebiotic as well. Oligosaccharides are one of the key 
components of the breast milk which can reach the colon and thereby contribute to the 
development of selective gut microbiota (204). So, regarding these two items, breast milk 
can be referred to as a synbiotic!  
3. Human milk also includes some immunological compounds like Lactoferrin and IgA. So 
in the end, through interaction with pathogens and helping colonization of the commensal 
bacteria (by preventing colonization and attachment of non-commensal ones), breast milk 
can contribute to shaping a normal microbiota (205).  
I.II.II. Lifestyle-related factors 
- Diet. Diet is obviously the most well-studied factor associated with gut microbiota 
composition and probably the most important one. The long-term effects of diet have been 
studied vastly and it has been demonstrated that diets full of fruit and fiber are associated 
with higher microbial diversity and a predominance of Prevotella over Bacteroides. In 
contrast, Western diets including high amounts of fat and/or sugar and low amounts of 
fiber, result in diminishing the SCFA producing Firmicutes and increasing enteric 
pathogens (206). In addition, in the last couple of years, two papers published in Science 
and Nature have revealed the importance of short-term diet on the alteration of gut 
microbiota composition (207, 208). Unsurprisingly, the significant association between 
specific diets and gut microbiota composition has been further confirmed by another two 
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key studies in the field (156, 163). In one of these studies, a negative association was 
revealed between all the Western-style foods and the microbiota diversity. Noteworthy, in 
this investigation, they could not find any association between carbohydrates and 
Prevotella to replicate previous results (156). However, in the Wang et al. study carried out 
on a decent sample size from two German cohorts, diet was shown to be associated with the 
gut microbiota signature but it merely could explain roughly 6% of all the variations (164).  
- Exercise. There are multiple, mainly animal studies, examining the effect of exercise on the 
structure of the gut microbiota. Human studies seemingly are more focused on comparing 
athletes with controls. For instance, one study in 2014 showed that athletes in comparison to 
control group had a more diverse gut microbiota structure which partly could be related to 
their different diet (high amount of protein consumption) (209). Moreover, another very 
recent Gut publication comparing professional athletes with sedentary controls has revealed 
that even SCFA (produced by gut microbiota), are increased in the athletes which is 
indicative of the importance of exercise at the levels of metagenomics and metabolomics in 
addition to the compositional level (210).   
I.II.III. Environmental factors  
- Geography. There are a couple of studies concentrating on the differences in gut microbiota 
composition based on geographical region. One study accomplished in the Jeffrey Gordon lab 
(2012), demonstrated that there are significant differences in the microbial composition of 
people residing in the US (metropolitan areas) compared to individuals living in the 
Amazonas of Venezuela and rural Malawian communities (211). Also, additional studies 
have indicated that people living in western countries harbor different microbiota compared 
to individuals living in under-developed countries (212, 213). These differences can be 
explained by differences in the genetic background and lifestyle including diet and hygiene. 
Moreover, a very interesting study on 1020 healthy individuals from 23 populations has 
displayed geographical latitude to be correlated with the abundances of Firmicutes 
(positively) and Bacteroidetes (negatively). The motivating hypothesis for this study 
originated from the observation of an increasing ratio between Firmicutes and Bacteroidetes 
in obesity and increasing of the body mass in the colder climates as an adaptation mechanism 
(214). Finally, another intriguing study on the residents of an absolutely isolated village in 
South America revealed the most diverse bacterial ecosystem ever observed in a human 
population. In addition, the genetic function of their microbiome showed the highest diversity 
(in fecal and skin samples). This became even more interesting when they found the 
functional antibiotic resistance (AR) genes among the microbiome of this population while 
they didn’t have any known exposure to antibiotics. This could be interpreted that those 
functional AR genes are a feature of the human genome regardless of its exposure to 
synthetic antibiotics (213)  
- Having Siblings. There are a few studies that have compared gut microbiota of infants with 
and without older siblings. Results in this field are still preliminary and contradictory, i.e. 
while one study has reported a decrease in the measurements of α-diversity in the infants with 
older siblings (215), these indices were shown to be increased in another study (216). Also, in 
the presence of controversies, it seems that not being the first child can result in having a 
more beneficial microbiota such as Bifidobacterium (217).  
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- Pet owning. There is no consensus in this area either. While Laursen et al. did not find a 
remarkable effect for furred pets on the infants’ gut microbiota composition (216), Azad 
showed that infants born in houses with pets have an increased gut microbiota richness and 
diversity (215). 
I.III. Microbial factors 
Although it potentially looks very important, thus far very little is known about the role of 
microbial factors in the stability of host-microbial composition. A key study in 2013, has 
defined a genetic locus, namely commensal colonization factors (ccf) which possibly could 
play a role. This locus harbors genes coding for polysaccharide utilization and has been 
shown to be conserved among different species of Bacteroides genus (one of the most 
prevalent genera established in the colon). This locus was discovered subsequent to the 
interesting observation of the resistance of germ-free mice mono-colonized with a 
single Bacteroides species to colonization by the same species while it was not the case for 
another species. Deletion of the genes mapped to the ccf loci in the murine model resulted in 
defective colonization and these genes were shown to be necessary for the Bacteroides re-
colonization after an induced microbiome disruption. Moreover, different independent studies 
confirmed a difference for the physical colonization location of the wild-type bacteria 
compared to the ccf-mutant harboring species in a way that only wild-type bacteria could 
reside within the intestinal crypts. Interestingly, crypt-associated species have been shown to 
be able to persist in the presence of antibiotic treatment (with the capacity of later 
repopulating the GI tract) which indicates the importance of this locus for the resilience and 
stability of Bacteroides in the complex composition of the gut microbiota (218).  
II. Dysbiosis 
In the next section, I will shortly describe some of the known factors implicated in disturbing 
the healthy composition of the gut microbiota and pushing it toward dysbiosis. 
Antibiotics and other xenometabolites. Thus far, a couple of dozen of medications have been 
shown to play a substrate role for microbial enzymes in the process of metabolism (158, 219).  
All of these xenometabolites which could target both human cells and microbes (antibiotics) 
could potentially change the microbial composition. Short-term and long-term effects of 
antibiotics on alteration of gut microbiota composition have been discussed for years (220, 
221). However, it should be pointed out that different bacteria react differently to exposure to 
different antimicrobials. For instance, the response of F. Prausnitzii to ampicillin and 
ciprofloxacin is increasing (by 4.5 fold) and decreasing, respectively (157). In recent years, 
the influence of host-cell targeted drugs has been studied as well. Among these, one can refer 
to metformin (222), proton pump inhibitors (223, 224) and rifaximin (225, 226). Moreover, in 
a very interesting study, Maurice et al. revealed that antibiotics and other xenobiotics could 
change the gene expression of the active phyla (primarily Firmicutes) of the gut microbiota in 
addition to its structure and diversity (157). 
- Smoking. It has been elucidated that gut microbiota composition in humans is affected by 
smoking. Seemingly most of the investigations in this area are concentrated on ex-smokers. 
In this regard, two studies have shown that gut microbiota of individuals who ceased smoking 
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is characterized by more Firmicutes and Actinobacteria and less Bacteroidetes and 
Proteobacteria (16, 227). Also, in one of these studies smoke quitting was associated with a 
more diverse microbiota composition (16). Zhernakova et al. studied the association between 
gut microbiota with being smoker or ex-smoker as well as having a smoker father or mother 
(during pregnancy). All these parameters were associated with microbiota diversity although 
the results were not very strong (156). In addition, it has been demonstrated that slightly more 
than 2% of the variation in the gut microbiota composition results from smoking (164). 
- Alcohol. Alcohol dependency can be associated with altered gut microbiota composition 
and function (228). Moreover, it has been demonstrated that the presence of alcohol could 
increase the growth of Gram-negative bacteria which can result in the accumulation of 
endotoxin and acetaldehyde in the colon. In this situation, acetaldehyde through some 
alterations in tight junctions could increase the intestinal permeability and result in the 
absorption of more endotoxin. Subsequently, this alcohol-induced bacterial endotoxin could 
be transferred to the liver as well as blood circulation which results in inflammation in the 
liver and many other organs (229). The mild association between microbiota composition and 
alcohol-containing products has also been demonstrated in Zhernakova’s publication (156). 
- Stress. Although most of the studies involved in the investigation of the gut-brain axis are 
interested in the effect of microbes on stress and controlling this by bacteria-containing 
products such as probiotics, there is evidence, originating from several studies, demonstrating 
a negative effect of stress on the gut microbiota composition (230-232). This effect could be 
mediated through some stress-induced modifications in the GI physiology and function such 
as alterations in the gut motility, inhibition of gastric acid secretion, and induction of the 
growth rate of Gram-negative bacteria (by norepinephrine). The overall impact of stress on 
gut microbiota composition has been summarized in a review article as an increase in the 
abundance of potentially pathogenic bacteria (e.g. Escherichia coli) and at the same time a 
decrease in the abundance of advantageous bacteria (such as Lactobacilli and 
Bifidobacterium) (233). 
III. Beneficial effects of the gut microbiota for host health  
Most of the gut microbiota are either harmless or beneficial for the host body. They have 
interactions with the body and influence it in different ways.  
Probably the most known influence of gut microbiota is its effect on the digestive system 
since most of the dietary fibers are not digestible by the enzymes of the small intestine (234), 
in contrast to gut microbiota which is a surprisingly rich source of enzymes that can digest 
these non-digestible carbohydrates.  
Digestion of low-digestible carbohydrates happens through fementation by Carbohydrate-
active enzymes (CAZymes), encoded by gut microbiome, which results in energy in the form 
of ATP and SCFAs as the end products of this fermentation process. SCFAs have been 
demonstrated to have numerous beneficial effects on the host body (235). Acetate, 
propionate, butyrate, isobutyrate, 2-methyl propionate, valerate, isovalerate and hexanoate are 
different SCFAs where the first three, are the most important ones. SCFAs (mainly butyrate) 
are the main energy source for colonocytes which keep them healthy and protect them from 
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colorectal cancer (236). Faecalibacterium, Eubacterium, Roseburia, and F. prausnitzii are 
among the bacteria known as SCFA producers (200, 237). Gut microbiota also has an 
extensive metabolic interaction with the host (238). It plays an important role in the 
regulation of glucose and cholesterol metabolism, i.e. it reduces plasma levels of glucose and 
cholesterol through different mechanisms and in this way could promote cardiovascular 
health (239). Another important impact of gut microbiota on the host physiology is akin to its 
effects on the functional structure of the GI tract including its influences on the tissue 
regeneration, gut barrier integrity, and morphogenesis of the GI vascular system (240). Gut 
microbiota also owns the interesting capacity of regulating the host immune homeostasis. 
Germ-free studies have shed light on the importance of the gut microbiota in the development 
of the host immune system. Both innate and adaptive immune systems have co-evolved with 
gut microbiota and these microorganisms play a special role in the maturation of gut-
associated lymphoid tissue (240, 241). Furthermore, gut bacteria can protect the host against 
entero-pathogenic microbes and finally help to have a normal immune system/function (155). 
Gut microbiota is also essential for the homeostasis of some other tissues of which 
homeostasis of bone mass through regulation of osteoclastogenesis is notable (242). 
Production of vitamin B12, vitamin K, folate, biotin, thiamine, and riboflavin, mainly done 
by Bifidobacterium, is another important role played by microbiota for the host. They also 
facilitate the absorption of dietary fats as well as fat-soluble vitamins via their effects on the 
bile acids (238). Bile acid signaling is a pathway through which the gut-liver axis works 
(243) and the gut microbiota plays a pivotal role in the homeostasis of the host’s bile acid 
pool through its different bile salt related enzymes (244). Another important everyday job 
done by microbiota is detoxification of harmful bioactive compounds in the host body. More 
than 40 bioactive compounds (either diet- or therapeutic- derived) have been recognized that 
need direct metabolic alteration by the bacteria in the body, among them xenobiotics (245). In 
relation to this, the gut microbiota plays an essential role in drug metabolism. Probably one of 
the most important reasons for the observed differences between individuals in response to 
drug therapy, which now is redirecting therapies toward personalized medicine, is the 
variation of gut microbiota composition among different individuals (246). Gut microbiota 
also has been shown to have an interaction with many host pathways, including the 
endocannabinoid system (247).  
IV. Dysbiosis induced effects  
Considering the immense interaction between gut microbes and the host, as well as the 
important roles played by these organisms, it is obvious that disturbance of this relationship, 
termed dysbiosis (248), may result in a plethora of pathological states/diseases in the host. A 
literature review shows that dysbiosis is associated with an emerging list of diseases which 
can be classified into two different categories of ‘extra-intestinal’ and ‘gastro-intestinal’ 
disorders.  
IV.I. Extra-intestinal diseases  
The mechanisms underlying many of these diseases are not crystal clear yet. However, 
abnormal intestinal permeability and microbial effects on epigenetic regulations are among 
the mechanisms possibly involved in the development of many of them. (249-251).  
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- Allergy (252, 253) 
- Ankylosing spondylitis (254) 
- Asthma (255) 
- Atherosclerosis and thrombosis risk (256) 
- Atopic dermatitis (257) 
- Autism (258) 
- Cardiovascular disorders(256, 259)  
- Cystic fibrosis (260, 261) 
- Depression (262) 
- Diabetes[I and II] (263, 264) 
- Multiple sclerosis (265, 266) 
- Neurodevelopmental disorders (267) 
- Obesity (170) 
- Parkinson’s disease (268, 269) 
- Psoriasis, Psoriatic arthritis (270) 
- Psychiatric and neurodegenerative disorders (256) 
- Renal disease (271) 
- Rheumatoid arthritis (272)  
IV.II. Gastro-intestinal disorders  
Numerous GI diseases have been recognized as being associated with an imbalanced 
relationship between gut microbiota and host. Among the important ones, I refer to:  
- Alcoholic and nonalcoholic fatty liver disease (273, 274)  
- Celiac disease (275)  
- Cholesterol gallstones (276)  
- Colon polyps (277)  
- Colorectal cancer (278, 279)  
- Infantile colic (280)  
- Inflammatory bowel disease (281)  
- Irritable bowel syndrome (282)  
- Liver cirrhosis (283, 284)  
- Mucositis and diarrhea (285)  
- Necrotizing enterocolitis (286)  
- Nonalcoholic steatohepatitis (287)  
- Pouchitis (288) 
 
Sections I to IV have been summarized in figure 9.  
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IV.II.I. Gut microbiota in IBS 
From a couple of years ago, an emerging number of studies have been published discussing 
the association between gut microbiota and IBS. They have been accomplished on fecal or 
mucosal samples from colon or small intestine. Different and sometimes contradicting results 
Figure 9. An overview of the physiological programming of a healthy gut, dysbiosis inducing 
factors and subsequent intra- and extra- GI disorders. 
 Antibiotics and other 
xenometabolites 
 Smoking 
 Alcohol 
 Stress 
 Surgery 
 Gastrointestinal infections  
Physiological programming Diseases 
Dysbiosis 
Intrinsic host factors 
 Genes 
 Age  
 Gender 
 Immune system 
 GI transit time 
 Fecal chromogranin A  
 Blood group 
 
Extrinsic host factors 
Mother induced 
 Mode of delivery 
 Mode of infant feeding 
 
Life style related factors 
 Diet 
 Exercise 
 Hygiene 
 
Environmental factors 
 Geography 
 Having siblings 
 Pet owning 
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with very low reproducibility have been reported from the different studies so far (table 5). 
For example, in a few studies comparing small intestinal bacteria of IBS patients with 
controls, one showed no difference (289) while another revealed different alterations (290).  
There is even no agreement regarding the overall changes in the total diversity and different 
publications have reported decreases, increases or no changes (282, 291-295). This amount of 
discordance could be related to several different factors. Patient characterization is one of the 
important factors discussed earlier. The small sample size of most studies could be another 
factor (292). Considering the complexity of the gut microbiota (comprising roughly 1000 
different species), and assuming a need for 10 subjects per variable to have an acceptable 
power, a ‘back of the envelope’ calculation displays a very far-reaching sample size (196). 
Also, it should be noted that gut microbes are very location-specific (296) and thus samples 
from different sections of the lower GI tract should be compared with caution. 
Results of a selection of the studies concerning dysbiosis in IBS have been presentd in table 
5. Having a closer look at this table led us to admit that with the present information, we can 
only claim that IBS is accompanied with microbial alterations. What exactly these changes 
are and whether these alterations are causal or only a simple association remains to be 
elucidated (154).  
To sum up, the importance of microbiota is not to be ignored and should seriously be taken 
into consideration although with caution.  
Table 5. Dysbiosis in IBS 
Study N Sample Microbial changes in IBS 
Si JM et al. 
(2004) (297) 
IBS: 25 
Ctrl: 25 
Stool Bifidobacterium , Enterobacteriaceae  
Malinen et al. 
(2005) (298) 
IBS: 27 
Ctrl: 22 
Stool IBS-C: Veillonella spp. 
IBS-D: Lactobacillus spp. 
IBS: Clostridium coccoides subgroup  
Bifidobacterium catenulatum group  
Mättö et al. 
(2005) (299) 
IBS: 26 
Ctrl: 25 
Stool Coliform bacteria (slightly),  aerob:anaerob 
ratio 
Maukonen et al. 
(2006) (300) 
IBS: 24 
Ctrl: 16 
Stool IBS-C: Clostridium coccoides-Eubacterium 
rectale group  
Sobieszczańska     
et al. (2007) (301) 
IBS: 44 
Ctrl: 34 
Stool Enteroaggregative E. coli strains  
Kerckhoffs et al. 
(2009) (302) 
IBS: 41 
Ctrl: 26 
Stool, 
Duodenal 
mucosa 
Bifidobacterium catenulatum  (in both samples) 
Krogius-Kurikka 
et al. (2009) (303) 
IBS: 10 
Ctrl: 23 
Stool IBS-D: Proteobacteria , Firmicutes 
(Particularly Lachnospiraceae family)  
Actinobacteria ,  Bacteroidetes  
Lyra et al. (2009) 
(304) 
IBS: 20 
Ctrl: 15 
Stool IBS-D: Ruminococcus torques ,  Clostridium 
thermosuccinogenes  
IBS-M: Ruminococcus torques ,  Clostridium 
thermosuccinogenes  
IBS-C: Ruminococcus bromii-Like  
Tana et al. (2010) 
(305) 
IBS: 26 
Ctrl: 26 
Stool Veillonella  
Lactobacillus  
Carroll IM et al. IBS: 10 Stool,  IBS-D: Aerobic bacteria  (in stool) 
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(2010) (306) Ctrl: 10 Colonic 
mucosa 
Lactobacillus spp.  (in stool) 
 
Noor et al. (2010) 
(307) 
IBS: 11 
Ctrl: 22 
Stool Bacteroides vulgatus , Bacteroides ovatus ,  
Bacteroides uniformis , Parabacteroides  
Kerckhoffs et al. 
(2011) (308) 
IBS: 37 
Ctrl: 20 
Stool, 
Small 
intestin 
mucosa 
Pseudomonas aeruginosa  (in both samples) 
Ponnusamy 
et al. (2011) (293) 
IBS: 11 
Ctrl: 8 
Stool Diversity of total bacteria  
Bacteroidetes , lactobacilli  
Bifidobacterium , Clostridium coccoides  
Rajilić-Stojanović 
et al. (2011) (309) 
IBS: 62 
Ctrl: 42 
Stool Firmicutes:Bacteroidetes ratio  
Dorea , Ruminococcus , Clostridium  
Bacteroidetes,  Bifidobacterium   
Faecalibacterium ,  Methanogens (when 
present)  
Parkes et al. 
(2012) (295) 
IBS: 47 
Ctrl: 26 
Rectal 
biopsies 
Total mucosa-associated bacteria  
Bacteroides , Eubacterium rectale-Clostridium 
coccoides 
IBS-D: Bifidobacterium   
Jeffery et al. 
(2012) (310) 
IBS: 37 
Ctrl: 20 
Stool Firmicutes-associated taxa  
Bacteroidetes-related taxa  
Jalanka-Tuovinen 
et al. (2014) (311) 
IBS: 37 
Ctrl: 20 
Stool PI-IBS and IBS-D: Several members of 
Bacteroidetes phylum  
uncultured Clostridia  
Rangel et al. 
(2015) (312) 
IBS: 33 
Ctrl: 16 
Stool, 
Mucosal 
biopsies 
Actinobacteria, Bacteroidetes, Bacilli, 
Clostridium clusters, Proteobacteria (in stool) 
Chung et al. 
(2016) (290) 
IBS: 28 
Ctrl: 19 
Stool, 
Jejunal 
mucosa 
Veillonellaceae (in stool)  
Prevotellaceae, Mycobacteriaceae , 
Neisseriaceae  (in jejunal mucosa)  
Firmicutes:Bacteroidetes ratio  (in stool)  
Firmicutes:Actinobacter ratio   (in jejunal 
mucosa) 
Ganji et al. (2016) 
(313) 
IBS: 80 
Ctrl: 50 
Stool Citrobacter , Lactobacilli , Actinomycetes  
Gobert et al. 
(2016) (314) 
IBS: 33 
Ctrl: 58 
Stool IBS-C: Bacteroides , Roseburia, 
Eubacterium rectale , Bifidobacterium and 
an increase of Enterobacteriaceae , 
Desulfovibrio  Akkermansia muciniphila  
Tap et al. (2017) 
(315) 
IBS: 110 
Ctrl: 39 
Stool, 
Mucosal 
biopsy 
Enterotype dominated by Bacteroides 
Ctrl: Controls, IBS: Irritable bowel syndrome cases, IBS-C: Constipation-predominant IBS, IBS-D: 
Diarrhea-predominant IBS, IBS-M: Mixed IBS, PI-IBS: Post-infectious IBS.  
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2  AIMS OF THE THESIS 
The overall aim of this thesis is to contribute to understanding the interplay between gut 
microbiota, gut function and human genes in the generation of gastrointestinal symptoms. 
 
More specifically the aims are: 
 
• To determine how the gut microbiota influence gastrointestinal function/symptoms in 
the general population in relation to physiological traits and symptoms such as stool 
frequency, stool consistency, and pain (papers I and II). 
 
• To characterize the association between human genes and gastrointestinal function 
(quantified by stool frequency as a surrogate marker for transit time) (paper III). 
 
• To characterize how host genes, gut microbiota and gastrointestinal function are 
interconnected in the development of IBS (papers IV and V). 
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3  MATERIALS AND METHODS 
3.1 Study population  
The main cohort exploited in this thesis project was the Population-based colonoscopy cohort 
(PopCol). This cohort has been exploited in all of the constituent papers of this thesis project 
and was the only sample source for the first and second papers. This cohort is described 
below. 
For the third paper, in addition to PopCol, a Dutch cohort, namely LifeLines-DEEP 
(described in detailed before (316)) was used. 
In the fourth publication, GWAS association results from TwinGene (part of the Screening 
across the Lifespan Twin study, SALT) were inspected, and replication of selected genes was 
performed in a Swedish case-control cohort. The SALT cohort encompasses 45,750 Swedish 
twins with extensive epidemiological data including GI symptoms, of which 11,326, mostly 
dizygotic twins, have GWAS genotyping data and were recruited in our study. This cohort 
has been described in another publication from our lab (93). The case-control cohort is a 
Swedish multicenter cohort including IBS patients (Rome III definition) and asymptomatic 
healthy controls described in detail in the supplementary material of the fourth paper. The 
PopCol cohort also was exploited in this study.  
For the fifth paper, the PopCol cohort, IBS cases and controls from the Swedish multicenter 
study, as well as sequencing data (of the SI gene) from seven IBS-D cases and one 
asymptomatic relative from four unrelated families, were used. The latter has been described 
in detail in the supplementary material of the fifth paper. 
3.1.1 Population-based Colonoscopy cohort (PopCol)  
For this cohort, 3347 Swedish adults (aged 18–70 years) were randomly selected, of which 
1244 accepted an evaluation by a gastroenterologist and subsequently, 745 volunteers agreed 
to undergo an Ileo-colonoscopy. Based on the assumption that the gut microbiota is mainly 
established during early infancy, persons born abroad were excluded. Likewise, people with 
any organic gastrointestinal disorders such as inflammatory bowel disease or celiac disease 
were excluded and offered standard treatment.  
Two subsamples of 264 and 204 subjects kept a detailed daily record of their bowel habits 
over 7 and 14 days respectively, of which 153 kept both (six years in between, on average). 
Moreover, close to the time of diary recording, subjects were asked to donate a fecal sample 
in addition to giving blood samples in the beginning of the study. At the end, we had different 
subsamples with different layers of data available from the first and second runs of data 
gathering which were used for the different studies (317). 
3.2 16S sequencing and data processing  
Two batches of fecal samples were collected over two time periods (from 2000 to 2012 with 
roughly 6 years in between samplings) and all the samples were stored at -80°C. EasyMAG 
NucliSens kits (Biomerieux) and Qiagen QIAamp DNA Stool Mini Kits, according to 
 35 
 
manufacturer’s instructions, were used for DNA extraction of the batches and extracted DNA 
was used at IKMB facility (Kiel, Germany) for amplicon sequencing.  
The V1-V2 hypervariable region from 16S ribosomal DNA was amplified using universal 
27F (5'-AGAGTTTGATCCTGGCTCAG-3') and 338R (5'-TGCTGCCTCCCGTAGGAGT-
3') primers and sequenced using MiSeq next-generation sequencing platform (Illumina. the 
USA). 
For data processing and quality control, raw paired-end reads of the coupled V1-V2 regions 
were merged using the fastq_mergepairs function of Usearch (v7.0.1090) (318). maxdiffs, 
minlen, minovlen, minmergelen, and maxmergelen were considered as 2, 200, 150, 270, and 
330, respectively. fastq_filter function (maxee: 0.1) from the same software was used to 
quality filter FASTQ reads and convert them to FASTA. Chimeric sequences were specified 
using the UCHIME_ref function of the usearch (v7.0.1090) software (319) applying the 
SILVA gold database (320) as the reference. To remove homopolymers longer than 8 
sequences, screen.seqs function was applied from Mothur (321). Sequences were classified 
applying classify.seqs command of mothur software, by using Silva bacterial reference and 
SILVA bacterial taxonomy files with a bootstrap value of 80% and applying 1000 iterations 
for the calculation of the bootstrap confidence score. Sequences related to chloroplasts, 
mitochondria, unknown, archea and eukaryotes were removed using remove.lineage function 
and the remaining sequences were aligned to the SILVA alignment database using align.seqs 
command implementing k-mer alignment procedure and non- aligned sequences were 
trimmed manually. Extra columns generated by alignment command were removed using the 
filter.seqs function and pre.cluster command was used for removing sequences that are likely 
due to sequencing errors. Then data was rarefied to 10,000 sequences per sample by 
subsample command. For defining OTUs, the dist.seqs command was used to make a 
distance matrix and reads were grouped using the average neighbour algorithm into OTUs 
(with 97% similarity) applying the cluster.split command (splitmethod=classify, taxlevel=4) 
and classify.otu (label=0.03) command was applied to get a consensus taxonomy for each 
OTU. 
3.3 Genotyping and quality control 
PopCol data genotyping was carried out using the Illumina HumanOmniExpressExome-8v1 
array containing 951,123 SNPs at the SNP&SEQ Technology Platform at Uppsala 
University, following the manufacturer’s protocol. SNPs with minor allele frequency and call 
rate smaller than 1% and 98% respectively, were excluded. Tests for the Hardy-Weinberg 
equilibrium were performed by the Fisher’s exact test to confirm (P > 10E-7) allelic 
equilibrium at each SNP site. Sample with call rate < 0.95 or genotype-phenotype sex 
mismatch were excluded. Related individuals were filtered out when genomic relatedness 
was > 0.15. Principal component analysis (PCA) was applied to control for population 
stratification. All the quality assurance steps were performed in SNP and Variation Suite 
(SVS) v8.3.3 (Golden Helix, Inc., Bozeman, MT, www.goldenhelix.com). 
Target genotyping of the TRPM8 and SI loci in the Swedish case-control cohort has been 
described in the supplementary materials of paper IV and V, respectively.  
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3.4 Statistical analysis  
3.4.1 Paper I. 
At the initiation of this study, no other study had been published to examine the association 
between surrogates of the transit time (stool frequency and consistency) and gut microbiota. 
However, before submission of our findings, two other papers (both examining only the stool 
consistency) were published in Gut (80, 81). Therefore, we decided to replicate their findings 
and expand them to include another surrogate of GI transit time, namely stool frequency. 
Thus, paper I includes only the methods and results relevant to those two studies. However, 
in addition to them, we have done some other analyses which have resulted in significant 
results (at the level of β-diversity measurements) and they will be presented here. 
In this study, after exclusion of the outliers, 69 individuals (48 women and 21 men, aged 
55.6±10.33) with available microbiota and fecal characteristics data were included in the 
study. Mean daily stool frequency and mean BSFS were calculated for all the participants.  
Moreover, the four different α-diversity measurements of observed species and Chao1 (as 
measurements of species richness), Faith’s phylogenetic diversity (PD, an index for 
phylogenetic diversity) and Shannon–Weaver entropy (as a measure of evenness), all at the 
level of OTU with 97% sequence identity (species-level), were calculated applying two R 
packages of ‘Vegan’ and ‘Phyloseq’.  
Distance matrices of Bray-Curtis (a statistics method used to quantify the compositional 
dissimilarity between two paired sites, based on the relative abundances of the studied taxa) 
and Jaccard (calculated based on the presence of a single taxa in paired samples) as well as 
Unweighted and Weighted Unifrac (β-diversity indices based on phylogenetic structure, and 
phylogenetic structure weighted by OTU abundances, respectively) were calculated using R 
packages of ‘Vegan’, ‘phyloseq’ and ‘Picante’. Adonis test (permutations=1000) was used to 
study the association between these matrices with ‘mean stool frequency’ and ‘mean BSFS’ 
after applying Cailliez correction for the negative eigenvalues (R package: ‘ade4’), adjusting 
for age and gender. 
Subsequently, taking advantage of the ‘PCoA’ function of the ‘Ape’ package, the inter-
individual relationships based on each distance matrix was calculated through 
principal coordinate decomposition analysis. Two first principal coordinates (for each matrix) 
were chosen to study in relation to the study variables of mean stool frequency and 
consistency with Spearman’s correlation test.  
In addition, the ratios between dominant phyla (Bacteroidetes:Firmicutes) and genera 
(Bacteroides:unclassified Ruminococcaceae) were calculated and their correlation with the 
study variables was assessed (Spearman’s correlation). This test was also used to investigate 
the relationship between stool frequency and consistency with the first 10 genera. 
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3.4.2  Paper II. 
For this study, 159 individuals (96 female and 63 male, aged 59.1±10.70) from the PopCol 
cohort with 16S sequencing data and daily recordings of abdominal pain (in a 14 days diary) 
collected over the same period (7.41±7.91 days in between) were included. Based on the 
diary information including number of episodes as well as the duration and intensity of each 
episode (score 1 for light pain, 2 for moderate pain and 3 for intense, unbearable pain), three 
variables of mean pain episodes per day, mean pain duration per episode and mean pain 
severity per episode were calculated (figure 10).  Accordingly, 52 individuals reported at least 
one episode of pain (assigned to the case group), whereas the other 107 persons did not report 
any pain even though they had filled the other sections of their diaries (assigned to the control 
group). Principal-coordinate analysis (PCoA) (based on Bray–Curtis and Jaccard dissimilarity 
matrices) was accomplished at both levels of genus and OTU 97%. The first three principal 
coordinates (related to each matrix and at both levels) were compared between cases and 
controls and studied in association to the three pain characteristics. P-values were corrected 
for multiple testing using the false discovery rate (FDR) method of Benjamini-Hochberg 
(applying FDR q-value threshold of < 0.1). Subsequently, study samples were classified into 
three clusters, namely enterotypes (149) according to their microbiota profiles at the genus 
level using R packages of ‘cluster’ and ‘clusterSim’ (for determination of the optimal number 
of clusters) following the tutorial available on http://enterotyping.embl.de/enterotypes.html. 
To further characterize the bacterial taxa potentially playing a role in the pain development, 
we took a closer look at the specific taxa previously associated with abdominal symptoms in 
the animal models and clinical studies. Abundances of 12 genera (Bacteroides, unclassified 
Ruminococcaceae, Butyricicoccus, Prevotella, Faecalibacterium, Streptococcus, 
Bifidobacterium Blautia, Akkermansia, Lactobacillus, Alistipes, and Enterobacter) were 
Figure 10. PopCol diary. Participants kept records for 7 consecutive days. 
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compared between cases and controls with Wilcoxon rank-sum test and p-values were 
corrected for multiple testing. Thereafter, multipatt function (func=‘IndVal.g’) of the 
‘indicspecies’ package was applied to accomplish an indicator value analysis on the core 
microbiota at the genus and species (OTU 97%) levels. Core microbiota included all the 
genera and species-level OTUs presented in at least 25% of the samples. To ensure that the 
results have been obtained independent of the IBS status, the analyses were repeated after 
exclusion of the 18 individuals whose questionnaire data were compatible with IBS diagnosis 
(according to Rome III criteria).  
3.4.3  Paper III. 
In total, 1546 participants from LifeLines-Deep (LLD) cohort (including 897 women (58%) 
and 649 men; mean age of 44 years (range 18–86)) and 264 individuals from PopCol cohort 
(encompassing 158 women (60%) and 106 men; mean age of 54 years (range 22–71)) were 
included in the study. Mean stool frequency per day was calculated for all the individuals 
based on the daily records kept by both populations for seven consecutive days. Genotyping 
data from both cohorts were imputed with IMPUTE2 (322) using the Genome of the 
Netherlands as the reference (323). Association testing was carried out within each cohort 
using linear regression tests under an additive genetic model (frequentist=1) adjusting for age 
and gender in SNPTEST (324) followed by a meta-analysis (fixed-effect model) with META 
(method 1) according to the instructions available at https://mathgen.stats.ox.ac.uk/genetics_ 
software/meta/meta.html.  
Genes mapped to the top-10 loci resulting from the meta-analysis were subjected to further 
investigation through Gene Network co-expression analysis (http://www.genenetwork.nl/ 
genenetwork/). Moreover, a suggestive threshold of p < 5E-05 was considered as the 
significance level and associated loci were defined with 250 kb window surrounding the lead 
Figure 11. An overview of methods applied in this study 
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SNPs. All the genes mapped to these loci were included in a gene set enrichment analysis 
(http://129.125.135.180:8080/Gene-Network/pathway.html) and p < 1E-04 was defined as 
the significant threshold for the gene ontology pathways. An overview of the methods applied 
in this study has been provided in figure 11. 
3.4.4 Paper IV. 
In total, 27 genes with GI-linked ion channel activity were inspected in the results from the 
GWA study of IBS accomplished previously by our group (93). They included gene families 
of ASIC (3 genes), CACNA1 (5 genes), HCN (1 gene) and KCN (4 genes), P2RX (3 genes), 
SCN (4 genes), TRP (6 genes) and ANO (1 gene). Significantly associated genes were 
subjected to a replication analysis in an independent cohort of IBS cases and controls. For 
this, a logistic regression analysis under an additive genetic model adjusted for gender was 
accomplished with SVS (v.8.3.4) on 386 IBS cases and 357 controls, followed by performing 
an analysis in each IBS subtype (IBS-C, IBS-D, and IBS-M defined based on Rome III 
criteria). Subsequently, a meta-analysis of GWAS and replication results was implemented in 
SVS using a fixed-effect model weighted by inverse­variance. Cochran’s Q test was used to 
test the heterogeneity of study results. Using the PopCol cohort, data from 120 IBS-free 
individuals were exploited to study the correlation between TRPM8 genotype and average 
BSFS scores by means of Spearman’s rank test in SPSS (v.22.0.0.0). In silico prediction of 
transcription factor affinity change was carried out using sTRAP tool (325). To do this, a 
sequence including a window of 10 nucleotides around the two SNPs of interest mapping to 
the promoter of the TRPM8 was selected and used as input for the analysis. In addition, the 
Genevestigator search engine was used to identify genes co-expressed with TRPM8. Probe 
signals with a correlation coefficient r > 0.25 in the Perturbation dataset (326) were filtered 
out. Transcription factors with a significant difference in the binding affinity and TRPM8 co-
expressed gene lists were subjected to gene set enrichment analysis to screen the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway (http://www.genome.jp/kegg/) 
database and the Gene Ontology (GO) terms of ‘Biological Process’, ‘Molecular Function’ 
and ‘Mammalian Phenotype’ with the Enrichr web-based software (327). All the steps have 
been briefly summarized in figure 12. 
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3.4.5 Paper V. 
Since the methodology of paper V has been very comprehensively described in the paper’s 
text and supplementary material, it is not elaborated on here. 
 
  
Inspection of association results for 
27 GI-related ion channel genes in 
the exploratory cohort (534/4932) 
Investigation of the significant 
results of the exploratory study in 
the replication cohort (386/357) 
Meta-analysis (920/5289) 
(exploratory + replication cohort) 
 
Study the association between 
TRPM8 and GI motility in PopCol 
(120 IBS-free individuals) 
Gene 
co-expression 
analysis 
Prediction of 
transcription 
factor binding 
Gene set enrichment analysis 
Figure 12. Flowchart of the study steps. 
(number of cases/number of controls) 
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4  RESULTS AND DISCUSSION 
 
4.1 Paper I. 
To investigate the link between gut microbiota and gut transit time, as an objective means to 
quantify GI functional abnormalities, we studied the association between different indices of 
fecal microbiota composition with stool consistency and stool frequency (as surrogates for 
gut transit time) in the PopCol cohort. The mean BSFS score and mean daily stool frequency 
of the participants were 3.91 (range 1.5–6) and 1.38 (range 0.57–3), respectively, and these 
two measures were significantly correlated (Spearman’s p=0.007, r=0.32). The microbial 
composition of each individual at two levels of phylum and genus is shown in figures 13 and 
14. Examining α-diversity, a negative correlation was detected between stool consistency and 
all four α-diversity indices. Of interest, studying the mean stool frequency resulted in even 
more significant and stronger correlations with all the α-diversity measurements (figure 15). 
At the level of β-diversity analysis and with applying Adonis test, only unweighted unifrac 
showed association (positive) with daily mean stool frequency (p=0.0079, R2=0.024). 
Testing for the interaction with age and gender, decreased the p-value slightly (p=0.0039). No 
significant association was observed regarding stool consistency. Moreover, testing the 
correlation between study variables and the first principal coordinate calculated based on 
weighted and unweighted unifrac as well as Bray-Curtis diversity indices (account for 15%, 
10% and 8.2% of variations, respectively) yielded significant results (figure 16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. The microbial phyla across the study individuals (n=61). 
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Studying the ratio between dominant phyla and genera in our dataset revealed significant 
correlations with mean stool frequency (phyla p=0.017 r=0.29; genera p=0.0001 r=0.45). 
However, mean stool consistency did not show significant correlation (p > 0.05). After 
exclusion of 9 individuals with the diagnosis of IBS, similar results were obtained. Our 
results could contribute to accumulating evidence linking gut microbiota to stool consistency 
as a surrogate of intestinal transit time. Reassuringly, this finding has been supported by 
results of the recent population-level study on a remarkable sample size from Belgium and 
the Netherlands, in which stool consistency demonstrated the largest effect size among 69 
different covariates explained to be associated with the variation in the microbiota 
composition (163). 
Figure14. The microbial genera across the study individuals (n=61). 
Figure 15. Correlation between different α-diversity indices and mean daily stool consistency and 
frequency. Stool consistency has been defined based on the BSFS. Reproduced from [Stool frequency 
is associated with gut microbiota composition, Hadizadeh F et al., 66, 559-560, 2016] with permission 
from BMJ Publishing Group Ltd. 
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    p-value = 7.74E-05   r = -0.45          p-value = 4.89E-05   r = 0.46 
  
p-value = 0.0033   r = -0.34 p-value = 0.024   r = 0.27 
 
 
p-value = 0.03   r = 0.25 
Figure 16. Correlation between β-diversity indices, stool frequency, and stool consistency. First 
principle coordinate (PCo1) of Principle coordinate analyses based on unweighted, weighted and 
Bray-Curtis diversity indices are plotted against Mean daily stool frequency and Mean BSFS (when 
significant) in different plots with their respective statistics.  
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Moreover, for the first time, we displayed that stool frequency as another surrogate of GI 
transit rate is associated with gut microbiota composition. This remarkable finding has also 
been supported later by another population-based metagenomics analysis on 1,135 Dutch 
participants which indicated both stool frequency and consistency among the top intrinsic 
factors associated with gut microbiota composition and interestingly, similar to our results, 
stool frequency showed a stronger association than stool consistency (156). Hypothetically, it 
could be a bidirectional association, and different factors can link microbiota composition to 
the GI transit time. Among them and in addition to what has already been discussed in the 
introduction, one can refer to the colon oxygen concentration which could be increased in the 
rapid transit state and possibly could be considered as a competitive advantage for aerobic 
bacteria over anaerobic ones. Intriguingly, in our study, we detected a negative association 
between the abundances of three anaerobic genera of unclassified Ruminococcaceae, 
Alistipes, and Oscillobacter with stool frequency. Also, a faster transit could be considered as 
a benefit for the fast-growing organisms which can prevail in the gut microbiota after the 
“washed out” situation resulting from diarrhea. On the other hand, slow transit time results in 
the very low nutrient content in the last segment of the colon which could result in increased 
abundance of the microbes with the ability to adapt to this situation (196, 311). Although the 
causal relationships and the direction of effects are yet far from understood, these findings are 
of importance because they may contribute to describing the potential role played by gut 
microbiota in host health maintenance and symptom generation. 
4.2 Paper II.  
To study the association between abdominal pain, the most important symptom of IBS, and 
gut microbiota, 52 individuals who reported pain (cases) and 107 controls were studied. The 
microbial composition of each individual at two levels of phylum and genus is shown in 
figures 17 and 18. On average, the number of pain episodes reported by the pain group was 
0.30 times per day (range 0.07–1.57) in which each episode lasted for 2.46 hours (range 
0.37–9 hours) with the mean intensity of 1.39 (range 1–2.1) that is categorized as light to 
moderated level. Applying Wilcoxon rank sum test, after multiple test correction (MTC), 
PCo1-Jaccard at the level of genera (q=0.017) and PCo3-Bray-Curtis, as well as PCo3- 
Jaccard at the level of OTU 97% (q=0.033 and 0.017, respectively), exhibited significant 
differences between cases and controls. Moreover, pain index scores for episode number, 
duration and severity appeared to be all significantly correlated (Spearman's) to different 
indices of β-diversity (figure 19). Subsequently, case and control groups were compared 
based on their enterotype distribution. Study samples were clustered into three enterotypes 
(enriched by unclassified Ruminococcaceae, Prevotella, and Bacteroides, respectively) and 
chi-square test demonstrated a significant difference between cases and controls (p=0.039) in 
which, the enterotype enriched by Prevotella was underrepresented in the pain group (21% vs 
41% in controls), while cases were more likely to fit into the third enterotype (enriched by 
Bacteroides) (figure 20).  
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These results remained constant after exclusion of the IBS cases (Prevotella 18% vs 40%; 
Bacteroides 46% vs 30% (case vs control); Pair-wise test p-value: 0.019). 
   
Cases (n=52) Controls (n=107) 
Figure 18. The microbial genera across the cases and controls. The individuals are sorted by the 
abundance of Bacteroides. 
Pain group 
(n=52) 
Control group 
(n=107) 
Figure 17. The microbial phyla across the cases and controls. The individuals are sorted by the 
abundance of Bacteroidetes. 
 46 
 
When cases and controls were compared for the abundances of the taxa previously linked to 
the abdominal symptoms in animal models and clinical studies, Benjamini-Hochberg 
corrected significant differences were observed for Prevotella (decreased in cases, q=0.038), 
Blautia (increased in cases, q=0.045), Streptococcus (increased in cases, q=0.038) and 
Lactobacillus (increased in cases, q=0.038). Moreover, ‘multipatt’ function of R package 
‘indicspecies’ represented Prevotella as the indicator of the no-pain group (q=0.016, 
stat=0.752). However, Lactobacillus which was observed to be an indicator for the pain 
group (p=0.0078, stat=0.64), after MTC was not significant anymore. Similarly, one 
OTU97% which belonged to the Prevotella genus and appeared as the indicator of the no-
pain group (p=0.0013, stat=0.581) lost its significance after MTC. 
Our study, at the general population level, could link the composition of the facal microbiota 
to the occurrence of abdominal pain as well as its characteristics including frequency, 
duration, and intensity. Also, we detected a negative association between Prevotella and pain 
which was supported by the difference in the distribution of enterotypes between cases and 
controls as well as by the indicator value analysis test. This finding in addition to the 
observation of an increase in the prevalence of the Bacteroides enterotype in the pain group 
parallels the observations previously made in IBS studies where the Prevotella-predominant 
enterotype was shown to be less common among the IBS patients while it was the other way 
around for the Bacteroides enterotype (315). This information, reported at the level of the 
general population, may contribute to translational opportunities for the identification and 
eventual treatment of individuals at risk for FGIDs and particularly IBS.  
  
Figure 19. Fecal microbiota β-diversity associates with abdominal pain. Heat map of Spearman’s 
correlation between pain indices and fecal microbiota β-diversity, based on principal coordinate 
analysis applied to Bray-Curtis and Jaccard matrices at the level of genera (Genera) and operational 
taxonomic units with 97% sequence similarity (OTU 97%). The first three principal coordinates (PC) 
are reported (PC1, PC2, and PC3) and significant correlations (false discovery rate < 0.1) are 
highlighted by a black frame. 
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4.3 Paper III.  
To investigate the genetic biology of stool frequency as a surrogate for gut transit time, after 
SNP and sample quality control, 5,390,800 SNPs (matched with diary data) for 1,022 LLD 
and 259 PopCol individuals were studied. None of the association test results passed the 
genome-wide significant threshold (5E-08) which could possibly be related to the limited 
number of the study samples. However, we could detect a couple of signals (the best SNP p-
value=4.8E-07) with excellent functional candidate genes mapping to them (figure 21). 
Among them is ALDH1A1 gene which mapped to the second strongest signal (on 
chromosome 9, the best SNP p-value=7.5E-07). ALDH1A1 gene is one of the family 
members of the aldehyde dehydrogenases. ALDH1L1 is another member of this family which 
has been reported to be associated with human gut microbiota composition. The aldehyde 
dehydrogenase coded by this gene is involved in formate oxidation which is a fermentation 
product and plays the role of electron carrier between interspecies syntrophs (172). 
Furthermore, gene network co-expression analysis indicated a role for ALDH1A1 as well as 
CYP8B1 (mapped to the third top signal) in the cytochrome P450 metabolism of drugs and 
xenobiotics. AHR, a gene mapped to another top-10 locus, is a transcription factor that can 
modulate gene expression along the cytochrome P450 pathway. Also, interestingly, CYB5R2 
(cytochrome B5 reductase), another gene mapping to one of the top defined regions, has been 
shown to be involved in the biosynthesis of cholesterol and desaturation and elongation of 
fatty acids. Considering a suggestive threshold of p < 5E-05, resulted in 53 loci. In a broader 
pathway analysis, including all the genes mapped to these loci, the cellular component class 
Figure 20. Fecal microbiota enterotype distribution differs between individuals with abdominal pain 
and controls. Principal component analysis (left) and relative distribution (right) of enterotypes 
according to the presence (case) or absence (control) of abdominal pain. Participants were classified 
into three enterotypes primarily characterized by unclassified Ruminococcaceae, Prevotella or 
Bacteroides. *p < 0.05.  
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of the GO identified the sodium channel complex (p=6E-07), voltage-gated sodium channel 
complex (p=2E-05) and ion channel complex (p=6E-05) among the most enriched pathways 
(p < 1E-04). In a similar manner, voltage-gated sodium channel activity (p=2E-05) and ion 
channel activity (p=4E-05) were displayed among the significant pathways in the GO terms 
derived from molecular function. 
The genetic contribution of xenobiotic and P450 metabolic pathways in the formation of 
human defecation patterns is not so surprising considering the known interactions linking 
diet, gut microbiota and pharmaceutical compounds, however, it has not been reported 
previously. Another remarkable finding of this study was related to the identification of the 
pathways linked to the voltage-gated sodium channels. Intriguingly, as described earlier in 
the introduction section, SCN5A gene has been implicated in the etiology of IBS in a subset 
of patients (mainly IBS-C) and is estimated to be potentially involved in gut motility (82). To 
conclude, we reported the results of the first GWAS of stool frequency in two coherent 
population-based cohorts from Sweden and the Netherlands and suggested possible candidate 
genes and biological pathways which could potentially be exploited by future investigations 
conducted on GI functions.  
 
  
Figure 21. Above: Manhattan plot of the meta-analysis results of the LifeLines-Deep and PopCol 
GWA studies. X-axis: SNPs sorted according to their genomic positions. Y-axis: negative 
logarithm of each SNP’s association p-value. Below: Table including the numbers of top-10 loci 
identified in the plot and their statistics in addition to their genomic positions, nearest gene, and the 
protein coding genes in 250kb loci around them. 
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4.4 Paper IV. 
Following the third study (described above), to further investigating the association between 
GI-related ion channel genes and IBS, the association results of the IBS GWAS (already 
accomplished by our group) were inspected for a number of GI-related ion channel genes. 
Four genes, including two genes from the calcium voltage-gated channels family (CACNA1A 
and CACNA1E) and two genes from the transient receptor potential channels family (TRPV3 
and TRPM8) displayed nominally significant association with IBS. In total, 33 SNPs were 
selected from these loci for a replication study. The logistic regression analysis of the 
genotype data from these four genes uncovered a significant association between TRPM8 and 
IBS. Subsequently, the meta-analysis of the 14 SNPs in this gene (TRPM8) from GWAS and 
the replication (case-control cohort), returned the strongest evidence of association at this 
locus with identical direction of the genetic risk effects in the two studies. Also, the 
Cochran’s Q test confirmed that there was no statistical heterogeneity between the two 
studies’ results (p > 0.05). Interestingly, performing the analysis in the IBS-subtypes revealed 
that the TRPM8 variations were exclusively associated with the IBS-C and IBS-M 
(constipation-related sub-types) and combining data from these two categories yielded the 
strongest evidence. Seven SNPs out of 14 were present in the PopCol genotype data 
(including 6 predisposing and one protecting). Intriguingly, investigation of the association 
between BSFS scores and TRPM8 genotypes, displayed a negative correlation between all 
IBS-C/M risk alleles and BSFS (consistent association between IBS-C/M risk alleles and 
harder stools) (figure 22). 
 
Figure 22. Correlation between TRPM8 genotype and average BSFS scores. Left: Spearman’s 
correlation statistics. Right: frequency of TRPM8 alleles across BSFS quartile groups (alleles from 
each SNP are color-coded as in the table on the left). 
 
Two SNPs with the strongest association with the IBS-C/M risk in the meta-analysis 
(rs10166942 and rs2362290) were mapped within the promoter region of the gene. In silico 
analysis predicted these variants to change the affinity of the transcription factor to their 
binding sites. Moreover, gene set enrichment analysis of the transcription factor pool affected 
by TRPM8 promoter SNPs, resulted in different enriched pathways and GO terms (after 
MTC), among them “abnormal hepatobiliary system” was enriched as the top scoring 
mammalian phenotype. In the same manner, co-expression analysis revealed 26 TRPM8 co-
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expressed genes of which GSE analysis returned “bile secretion”, “bile acid and bile salt 
transport” as well as “bile acid metabolic process” as the main GO biological process terms. 
These findings are potentially important. Functional dysregulation of transient receptor 
potential (TRP) channels has already been shown to associate with constipation and IBS 
(328). Furthermore, interestingly, it has been demonstrated that peppermint oil (containing 
the TRPM8 activator menthol) could relieve IBS symptoms (63, 329). Our findings of the 
association between TRPM8 SNPs with slower colonic transit, constipation, and IBS could 
contribute to the understanding of the pathophysiological mechanisms underlying IBS. On 
the other hand, the regulatory mechanisms for TRPM8 expression are not well characterized 
yet and modifications of the bile acid synthesis and metabolism, which has been shown to be 
associated with constipation and IBS could be considered as a potential mechanism (330).  
To sum up, for the first time we identified TRPM8 polymorphisms to be associated with 
increased risk of IBS with constipation (IBS-C and IBS-M) and slower colonic transit time. 
These findings may contribute to identifying subsets of IBS patients and eventually result in 
the improvement of their diagnosis and clinical management. 
4.5 Paper V. 
In view of the speculated effects of specific foods in triggering IBS and the reports of IBS-
like symptoms in patients with CSID (caused by SI mutations), we were motivated to 
investigate the possible role played by this enzyme (SI) in the development of IBS. To detect 
the SI variants with potential relevance to IBS development, four unrelated IBS-D families 
including seven postprandial IBS-D cases and one control (asymptomatic family member) 
were selected for sequencing of the SI gene. No new SI mutation was identified in this effort 
and all family members had two reference alleles of all common coding variants, except at 
two sites. Because together there are only three common missense SNPs in the SI gene, all 
three missense SNPs of p.Thr231Ala, p.Met1523Ile, and p.Val15Phe were investigated for 
their deleteriousness in silico (using CADD scores). While the first two were not classified as 
deleterious (bottom 90% of the variations ranked by deleteriousness), p.Val15Phe was ranked 
among the top 1% most deleterious amino acid substitutions in the human genome (similar to 
known CSID mutations). Interestingly, this SNP was detected in six cases out of the seven (in 
the family study) and was shown to cosegregate with IBS. Therefore, this SNP was selected 
for further studies and characterization. In vitro functional characterization of this coding 
SNP through comparison of the functional properties of 15Val and 15Phe, demonstrated 35% 
reduction of the total enzyme activity for the 15Phe. The next step was dedicated to the study 
of the association between four known CSID mutations (p.Val557Gly, p.Gly1073Asp, 
p.Arg1124Ter and p.Phe1745Cys) as well as the p.Val15Phe variant with IBS. Studying the 
association of the CSID mutations and IBS in a cohort of 1887 individuals from four 
independent IBS case-control cohorts showed a trend for IBS patients to have a higher odds 
of carrying one of the CSID mutations compared to the control group, which was 
consolidated by checking public data from a reference panel of > 31,000 sequenced data from 
the European Exome Aggregation Consortium. Moreover, a positive association between 
15Phe and IBS was detected exploiting data from the four independent IBS case-control 
cohorts (p=0.0030, OR=1.26) with the best evidence of association with the diarrhea-linked 
subtypes (p=0.00051, OR=1.34 for the IBS-D/IBS-M combined) (logistic regression under 
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additive model adjusted for sex and enrollment center). Furthermore, these results (from the 
pooled analyses of all the cohorts) were strongly supported by a meta-analysis of associations 
from individual cohorts. 
The next step was to investigate 15Phe in relation to bowel function, symptoms and 
microbiota composition in the general population. To do this, data related to 250 individuals 
from the PopCol cohort including 30 IBS cases was exploited. Although the sample size was 
small, a significant positive association between 15Phe and IBS risk was observed (p=0.045, 
OR=1.89) which again was stronger for IBS-D/IBS-M (p=0.013, OR=2.50). Combining case-
control and PopCol data further strengthened the results particularly for the diarrhea-related 
subtypes (combination of IBS-D/IBS-M p=0.00012, OR=1.36). To study the association 
between carrying the risk allele and bowel function, a subset of 133 individuals with daily 
recordings of stool frequency was selected. A significant positive correlation was detected 
between mean stool frequency and the number of 15Phe copies (p=0.026, r=0.19). However, 
no significant association was observed in relation to stool consistency. To examine the 
potential association between fecal microbiota and the number of risk alleles, data from 136 
individuals from the PopCol cohort with available 16S rRNA sequencing and genotyping 
data were included in the study. A core microbiota of 20 of the most abundant genera was 
selected and tested in association with the number of 15Phe copies using Pearson’s 
correlation. A Bonferroni-corrected significant inverse correlation was observed between the 
abundance of Parabacteroides and the number of 15Phe copies (Figure 23).  
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In summary, this study demonstrated an association between genetic variation in the sucrase-
isomaltase gene and predisposition to IBS which was detected principally in the diarrhea-
related IBS. This notion is noteworthy because it may help identify a subgroup of IBS 
patients with genetic susceptibility to disaccharide maldigestion, which could eventually 
result in taking advantage of personalized medicine approaches to improve their 
management. 
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Figure 23. Fecal microbiota abundance of Parabacteroides correlates with p.Val15Phe genotype. 
Above: Stacked barplots show the frequency of 20 most abundant genera across three genotypes. 
Below: Beeswarm plots depict the relative abundance of Parabacteroides (sequence counts/10000) 
for PopCol individuals (dots) stratified according to genotype at the p.Val15Phe SNP site. The 
distribution of the data is reported as box plots for each genotype group.  
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Moreover, as described in the introduction, some nutrients such as carbohydrates are believed 
to play a trigger role in many IBS patients. Intriguingly, our findings could provide a 
biological basis for this belief by displaying the potential interplay between defects in 
carbohydrate digestion enzymes, alterations in the GI transit rate and gut microbiota 
composition.  
Finally, the pilot study using PopCol displayed an association between SI genotype variant 
p.Val15Phe and the fecal concentration of Parabacteroides. This is intriguing because, in 
agreement with this finding, the fecal abundance of this genus has been revealed to have a 
negative correlation with a higher intake of dietary carbohydrate (207) and in some studies 
Parabacteroides have been shown to be under-represented in IBS sufferers (307, 312). Thus, 
if confirmed by further studies, the inverse association between 15Phe copy number and 
Parabacteroides abundance may contribute to the identification of IBS patients with SI 
defects. 
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5  CONCLUDING REMARKS 
The work presented in this thesis mainly concerns an attempt to further understand the 
interplay between gut microbiota, gut function and human genes in the generation of 
gastrointestinal symptoms. 
In paper I, we provided more evidence for the association between gut microbiota and stool 
consistency and also for the first time displayed an association between fecal microbiota and 
stool frequency. Both of these fecal characteristics are considered as surrogates for GI transit 
time which in turn is used as an objective method to quantify GI functional abnormalities and 
has been shown to be associated with many GI functional symptoms. In paper II, we 
demonstrated an association between gut microbiota composition and abdominal pain 
occurrence as well as its frequency, duration, and severity. Also, we could provide more 
evidence for the negative association of Prevotella with pain in the general population. In 
paper III, for the first time, we could link human genes to GI function quantified by stool 
frequency in a genome-wide association study of two harmonized general population cohorts 
and suggested xenobiotic metabolism and ion channel activity as two plausible underlying 
mechanisms for the regulation of stool frequency. In papers IV and V, we identified two 
genes whose variants are associated with IBS and colonic transit rate. Of particular interest, 
these genes showed a stronger association with different subtypes of IBS (TRPM8 variants 
showed a stronger association with IBS-C while SI SNPs were more linked to IBS-D) which 
suggests a possible genetic ground for stratification of IBS sufferers in the future. Also, 
paper V, through a combination of genetic results with phenotypic characteristics and 
microbiota-related findings could be considered as the first experimental evidence pointing to 
nutrigenetic mechanisms associated with IBS susceptibility and symptom generation.  
The information resulting from this thesis project may contribute to translational 
opportunities for the stratification and eventual management of individuals with IBS and 
other FGIDs. Finally, the thesis was carried out based on a very ambitious aim and we have 
hopefully succeeded to some degree in shedding more light on the phenomenally complex 
interplay between the several different elements involved in the generation of GI symptoms.  
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